key: cord-0040892-x661u6w2
authors: Berry, Gerald J.
title: Lung Transplantation
date: 2016-09-16
journal: Pathology of Transplantation
DOI: 10.1007/978-3-319-29683-8_5
sha: 9a132551015b409f545c695795773e564f42cb33
doc_id: 40892
cord_uid: x661u6w2

The therapeutic options for patients with advanced pulmonary parenchymal or vascular disorders are currently limited. Lung transplantation remains one of the few viable interventions, but on account of the insufficient donor pool only a minority of these patients actually undergo the procedure each year. Following transplantation there are a number of early and late allograft complications such as primary graft dysfunction, allograft rejection, infection, post-transplant lymphoproliferative disorder and late injury that is now classified as chronic lung allograft dysfunction. The pathologist plays an essential role in the diagnosis and classification of these myriad complications. Although the transplant procedures are performed in selected centers patients typically return to their local centers. When complications arise it is often the responsibility of the local pathologist to evaluate specimens. Therefore familiarity with the pathology of lung transplantation is important.

The therapeutic options for patients with advanced pulmonary parenchymal or vascular disorders are limited. Lung transplantation remains one of the few viable interventions, but on account of the insuffi cient donor pool only a minority of these patients actually undergo the procedure each year. Further, the projections for the number of lung transplant candidates will continue to increase with our expanding older patient demographic. Despite the increase in transplant procedures annually, the problem of organ availability and suitability will likely persist. A number of solutions for expanding the donor pool have been implemented or are under active experimental or clinical investigation, including changes in the allocation methods, interventions such as extracorporeal membrane oxygenation (ECMO) and ex vivo lung perfusion and utilizing older donor organs and organs procured following circulatory cessation or donation after circulatory determination of death (DCDD). Following transplantation there are a number of early and late allograft complications such as primary graft dysfunction, allograft rejection, infec-tion, post-transplant lymphoproliferative disorder and late injury that is now classifi ed as chronic lung allograft dysfunction. The pathologist plays an essential role in the diagnosis and classifi cation of these myriad complications. Although the transplant procedures are performed in selected centers patients typically return home after a period of convalescence and observation. When complications arise thereafter it is often the responsibility of the local pathologist to evaluate the laboratory, cytopathologic and histopathologic studies. For these reasons familiarity with the pathology of lung transplantation is important.

The initial experimental attempts at lung transplantation date back over a century ago when Guthrie and Carrel implanted the heart and lungs of a kitten into the neck vessels of an adult cat [ 1 ] . Forty years later, the Russian physiologist Demikhov developed canine models of combined heart-lung and single transplantation [ 2 , 3 ] . In the early 1960s, Hardy and colleagues at the University of Mississippi performed the fi rst human lung transplant in 1963 in a 58-year old man with advanced lung cancer. He survived 18 days, but succumbed to renal failure ; no acute cellular rejection ( ACR ) was found at postmortem examination [ 4 ] . The fi rst Canadian lung transplant was performed in 1966. The recipient was a 31-year old man with advanced silicosis and he survived only 7 days. At postmortem, the transplanted lung showed ACR , preservation injury, and necrosis of the proximal bronchus [ 5 ] . In 1968, Cooley attempted the fi rst human combined heart-lung transplant on a 2-month old child with complex congenital heart disease, but she died 14 h later from respiratory failure [ 6 ] . Shortly thereafter, Lillehi and colleagues performed the procedure in an adult recipient with chronic obstructive pulmonary disease ( COPD ) and cor pulmonale with survival of only 8 days. Attempts at lung transplantation sputtered over the next decade with many centers abandoning their programs on account of dismal survival results attributable to insuffi cient immunosuppression and/or technical diffi culties such as anastomotic dehiscence [ 7 ] . With the initiation of the cyclosporine era in 1980, there was resurgence in interest in combined heart-lung transplantation by the Stanford team and lung transplantation in the Toronto program. This novel form of immunosuppression permitted reduced corticosteroid dosages and led to a reduction in anastomotic complications. Reitz et al. at Stanford [ 8 ] overcame a series of technical and immunosuppressive liabilities utilizing a nonhuman primate model before achieving successful long-term survival in their clinical program. Four of the fi ve patients transplanted for advanced pulmonary vascular disease (either idiopathic pulmonary arterial hypertension ( IPAH ) or complex congenital heart disease with Eisenmenger's physiology) survived beyond a 6-month period of follow-up.

Shortly thereafter, Patterson and Cooper [ 9 ] at the University of Toronto reported the fi rst successful single lung transplant program for patients with end-stage pulmonary fi brosis. The technique for double lung transplant evolved from the en bloc approach with tracheal anastomosis to the current bilateral sequential single lung transplant technique [ 10 ] . Lung transplantation in the pediatric population was introduced in 1986 and the fi rst procedure in an infant was reported in 2000. The living-related lobar transplant program was initiated by Starnes and his colleagues in the mid-1990s and has now expanded to cadaveric lobar lung transplantation [ 11 -14 ] . Excellent results have been reported from experienced centers.

Over the last three decades, the indications for combined heart-lung and lung transplantation have expanded. In adults, the main indications are COPD including emphysema and alpha-1-antitrypsin defi ciency, suppurative lung disease/cystic fi brosis ( CF ), fi brotic interstitial lung disease ( ILD ) including idiopathic pulmonary fi brosis (IPF), chronic hypersensitivity pneumonitis, and nonspecifi c interstitial pneumonia (NSIP), and pulmonary vascular disease including IPAH and Eisenmenger's physiology ( Fig. 1 ) In the most recent published data from the ISHLT registry , there has been a sevenfold increase in the number of lung transplants since 1990, with 33,893 lung transplants reported in 2013 and a total of 51,440 lung and 3820 heartlung procedures recorded up to mid-2014 [ 15 ] . The median survival is 5.6 years with bilateral/ double lung recipients having much better median survival rates compared to single lung transplant patients (7.1 versus 4.5 years). Over the last 15 years, there has been a shift from single lung to bilateral/double lung transplant as the preferred surgical procedure. One hundred and twenty four pediatric lung transplant procedures were performed in 2013. In infants and children , there are unique pediatric conditions that require transplantation in addition to the suppurative and pulmonary vascular categories. In infants under the age of 1 year, the most common indications are IPAH or other vascular disorders, congenital heart disease, and surfactant defi ciencies, while in the childhood group (1-5 years) IPAH and pulmonary fi brosis account for the majority of cases. In children older than 6 years, the most common indication is CF [ 16 ] . The median survival is comparable to the adult group at 5.3 years with bilateral/double recipients faring much better than single lung recipients. There has been a steady decline in the number of combined heart-lung transplants in adults since 2000 with median survival rates in patients transplanted in the most recent era now similar to the lung group (5.6 years). Patients with CF , congenital heart disease, and IPAH constitute the vast majority of these cases.

Historically, the "time on the wait list" has been the traditional approach to prioritizing and apportioning lung allografts. In 2005, the lung allocation score ( LAS ) was introduced in the United States to prioritize patients on the wait-list for lung transplants based on the urgency of the patient's condition and the likelihood of survival after transplant [ 17 ] . The LAS represents a paradigm shift in transplant medicine utilizing a statistical modeling approach that calculates a "waiting list urgency measure" and a "posttransplant survival measure." A numeric transplant benefi t is calculated from the simple subtraction of these entities and then a normalized LAS is enumerated by a mathematical formula. The LAS score then determines the placement with higher scores refl ecting sicker patients with greater expected benefi t. Although still controversial, there are published data showing reduction of both the number of deaths on the waitlist and waitlist times (from years to months) [ 18 -20 ] . It has also led to an increase in the proportion of patients transplanted for IPF and a decline in those transplanted for COPD [ 15 ] . There have been a number of recent studies that have shown that the overall survival time has not changed, refl ecting the problem that sicker patients are now being transplanted. Not surprisingly, patients with high LAS scores have higher post-transplant complications [ 20 ] . The LAS approach has also had an impact on the selection of transplant procedure (single versus bilateral/ double lung transplant) [ 21 ] . The impact of organ distribution in the pediatric setting is signifi cantly more controversial, particularly in children under the age of 12 years [ 22 , 23 ] . In this age group, the combination of group waitlist times and a Priority 1 scoring system is used [ 23 , 24 ] . The LAS system is utilized for children older than 12 years of age in the US. Infants may be considered for an ABO-incompatible procedure as they have not yet developed preformed antibodies against ABO blood antigens, but there is very little published clinical experience with this approach [ 25 ] .

The current criteria for donor acceptability were recently summarized by the ISHLT [ 26 ] . These refl ect in large part the accumulated historical experience of transplant programs and a conservative approach to donor evaluation. Briefl y, the " ideal donor " would have most or all of the following characteristics : age under 55 years, ABO blood compatibility, normal chest X-ray, and absence or limited smoking history (<20 packyears), comparable size matching, graft ischemia time of less than 6 h, and absence of aspiration or septic episodes, prior thoracic surgery, prior malignancy, organisms on a sputum gram stain, or purulent secretions at the time of bronchoscopy. Strict adherence to these requirements has traditionally resulted in limited utilization rates of potential allografts in the range of 5-20 %. Over the past decade, a number of studies have questioned some or all of these criteria and many centers have focused on revised criteria to assess and potentially accept more donor lungs. Snell and colleagues have sub-classifi ed this " extended donor pool " into two groups: (1) General medi-cal issues such as prior history or age, and (2) Specifi c medical issues such as infection, pulmonary edema, etc. [ 27 ] . Both categories may have potential clinical consequences for the recipient such as late complications in the fi rst group and primary graft dysfunction ( PGD ) and other early complications in the second group. On occasion, the pathologist may be asked to perform frozen-section examination of a pulmonary nodule or consolidation in a potential donor situation. Tissue should be sent for microbiologic testing in all cases and histochemical or immunohistochemical staining for bacterial, fungal, or viral organisms should be obtained on the permanent sections as warranted.

In addition to loosening many of the historic contraindications to donor suitability, a number of molecular and surgical techniques and potential donor sources have been adapted to the evaluation process.

Donation after cardiac death . Until recently, the vast majority of lung donor allografts were cadaveric organs retrieved following brain death. In addition to the living-related lobar donations described previously, attention is now focused on the potential role of cadaveric donation after circulatory cessation/determination of death ( DCDD ) . Based on a series of elegant experiments in a canine model by Egan et al. and other investigators, it was determined that the lung utilizes passive diffusion throughout the alveolar parenchyma rather than direct perfusion as a mechanism for aerobic metabolism. As a result, the lung has an extended period of viability following circulatory arrest [ 28 -30 ] . In several centers, this method of organ procurement has been adopted into their clinical programs. There are limited published survival results, but most series suggest comparable or slightly better results at time points in the fi rst 2 years after transplant [ 31 -34 ] . A recent report raised concern for the diminished survival and freedom from bronchiolitis obliterans syndrome ( BOS ) in this group compared to the traditional group and therefore additional medium-and long-term studies are needed [ 35 ] .

Ex vivo perfusion/resuscitation. Ex vivo lung perfusion ( EVLP) represents another modality directed at expanding the donor pool. Lungs with traumatic injury, pulmonary edema, or infection can be evaluated for likelihood of the reversibility of the injury pattern and initiation of therapeutic interventions for potential salvaging and utilization. The technique has been used in selected centers in Europe and North America in both the experimental and clinical settings. Studies by Steen and colleagues in Sweden and Cypel and colleagues in Toronto utilize continuous anterograde perfusion with a hyperoncotic acellular preservation solution and ventilation of the lungs by ventilator at a normothermic setting [ 36 , 37 ] . Deoxygenation of the perfusate is manipulated by an oxygenator containing hypoxic gas. The technique allows lung perfusion for up to 12 h. Recent studies by the Toronto group have also demonstrated the utility of gene therapy with adenovirus vector encoding human interleukin-10 to reverse the pro-infl ammatory milieu of the injured lung [ 38 ] . Only a few limited long-term results have been reported in the literature, but they show similar outcomes in DCDD with EVLP compared to transplant following brain death [ 39 -41 ] .

Molecular evaluation of the donor . One of the early complications after transplantation is the development of primary graft failure ( PGF ) . Its severity is variable, but it can lead to increased morbidity and mortality. Although some risk factors have been enumerated, there are no specifi c biomarkers. Recently, molecular techniques have been implemented and show promise for future clinical application. Kaneda and colleagues [ 42 ] investigated cytokine mRMA expression from lung biopsy samples obtained before implantation of the allograft. A step-wise logistic regression analysis for 30-day mortality found that the ratio of IL-6/IL-10 was most predictive ( p = 0.0013). Using a gene expression profi le technique, Anraku and colleagues [ 43 ] found that the overexpression of four genes ( ATP11B, FGFR2, EGLN1 , and MCPH1 ) was predictive for the development of PGF . In another study from the Toronto group [ 44 ] , lung allografts with low surfactant protein-A mRNA expression prior to implantation exhibited reduced survival. In their most recent molecular work, pre-implantelevated levels of IL-6 mRNA correlated with the subsequent development of the BOS component of chronic lung allograft dysfunction ( CLAD ) [ 45 ] . Other molecular approaches to the lung allograft have identifi ed innate immune and infl ammatory pathways that may be responsible for post-transplant parenchymal injury [ 46 , 47 ] . Further studies will be needed to confi rm the predictive and prognostic utility of these molecular studies .

The ISHLT recently updated the guidelines for the selection and evaluation of patients for lung transplantation [ 48 -50 ] . In addition to general criteria for candidate consideration such as the high risk of death from lung disease within 2 years and the high likelihood of survival for at least 3 months after transplant, the guidelines enumerate both absolute and relative contraindications to transplantation. As with all guidelines, these recommendations are based on current "state-of-the-art" and will likely undergo further revision with the emergence of new insights [ 51 ] . Special emphasis is placed on the indications for "bridging to transplant" using modalities such as mechanical ventilation , extracorporeal membrane oxygenation ( ECMO ) , and other forms of extracorporeal life support systems [ 52 -54 ] .

As previously discussed, the common indications for lung transplant in adults include ILD , COPD , CF , and pulmonary vascular disease . A comprehensive evaluation must include not only the timing for the patient referral and the timing of listing after the evaluation, but also the likelihood of recovery and projected survival for 5 or more years. There are important issues in each of these categories for which the pathologist and the laboratory play an essential role. These will be briefl y highlighted in the next section.

As previously discussed, the implementation of LAS system in the US and Eurotransplant programs has led to a sharp increase in the rates of lung transplants undertaken for ILD . There are unique issues related to ILD and the timing of the referral for transplant evaluation and the timing of listing for transplant. Many, but not all, patients will have had video-assisted thoracoscopic surgery ( VATS ) biopsies as part of their diagnostic work-up and it is important to have the biopsy reviewed for accurate classifi cation. There is a difference in the rate of progression and prognosis of usual interstitial pneumonia ( UIP ) and NSIP. With the introduction of pirfenidone in the treatment of IPF, the pace of the disease as demonstrated by lung function, exercise tolerance, and survival has been altered [ 55 ] . Further, the diagnosis of chronic hypersensitivity pneumonitis should warrant a careful occupational, drug, and environmental exposure history to eliminate the risk of disease recurrence in the allograft. In some cases, the diagnosis of ILD is associated with a collagen vascular disorder and patients with scleroderma-associated ILD should be carefully evaluated for concurrent pulmonary hypertension or malignancy .

CF is a common indication for transplant in children, adolescents, and adults. It is a progressive disease characterized by repeated episodes of infection and may be complicated by acute respiratory failure, development of antibiotic resistance, pneumothorax, hemoptysis, and general nutritional decline. In general, these patients are not biopsied prior to transplant, but they are susceptible to two important infectious complications. There is an increased risk for non-tuberculous mycobacterial ( NTM ) infections such as M. abscessus [ 56 ] . Patients with culture-positive NTM are aggressively treated with antibiotic therapy. The presence of progressive pulmonary NTM despite medical therapy or extrapulmonary NTM is considered to be a contraindication to transplant by most programs.

Another infectious complication in CF patients is Burkholderia cepacia complex. It is investigated as part of the transplant evaluation. It is recognized as a relative contraindication to transplant, but many programs do not transplant this group of patients on account of the high rate of recurrence after transplant and resistance to antibiotic therapy. These patients have poorer outcomes after transplant [ 57 ] . There are, however, selected centers with experience in the treatment of B. cepacia complex that will accept these patients for transplant .

COPD is another slowly progressive disease that has unique issues related to the timing of evaluation and listing for transplant. Frequent, severe clinical exacerbations, severely impaired PFTs, and the development of moderate or severe pulmonary hypertension are some of the indications for listing patients for transplant [ 50 ] . Patients with bullous disease may be candidates for lungvolume reduction surgery ( LVRS ) that may temporize the decline in pulmonary function. The surgical specimens should be carefully evaluated for smoking-related disorders such as pulmonary Langerhans cell histiocytosis, granulomatous infection, and pulmonary neoplasia as they can have potential consequences in the transplant setting [ 58 ] .

Pulmonary vascular disease . The introduction of effective medical therapy for the treatment of pulmonary arterial hypertension has affected the timing for transplant referral and subsequent listing of patients. Over the course of the last two decades, the percentage of patients transplanted for IPAH has dropped from 11.8 % in 1991 to 2.7 % in 2011. Patients with IPAH and hypertension associated with other conditions (WHO Groups I and III) benefi t from the prostanoids, endothelin receptor antagonists, and phosphodiesterase inhibitors [ 59 ] . Lung biopsies are rarely performed in these patients. The accurate classifi cation into one or more pathologic categories such as pulmonary arteriopathy, pulmonary occlusive venulopathy, and pulmonary microvasculopathy is generally reserved for the explanted lung specimens [ 60 ] . There are case reports of recurrent pulmonary microvasculopathy (formerly pulmonary capillary hemangiomatosis) following lung transplant [ 61 ] .

Multi-organ transplant . Over the last decade, the indications for multi-organ transplant besides combined heart-lung transplant have also expanded. Concurrent thoracic and abdominal transplants are performed on carefully selected patients in specialized centers. Wolf and colleagues recently reviewed the accumulated multicenter experience and identifi ed 42 combined lung-liver (Lu-Li) transplants and 18 simultaneous lung-kidney (Lu-Ki) through 2010. Of the patients listed for Lu-Li transplant, CF and pulmonary hypertension accounted for the vast majority of lung disorders, while ILD and pulmonary hypertension were responsible for most of the pulmonary disorders in the Lu-Ki group [ 62 ] . Interestingly, the outcome for the two groups was similar to thoracic transplant patients in general (and slightly worse than their abdominal transplant counterparts). The pathologist is responsible for the careful histopathologic examination of each organ and should follow the guidelines for the pathologic examination of the explanted organ for each component .

Lung transplant for pulmonary adenocarcinoma . Patients undergoing lung transplant for COPD, ILD , and collagen vascular disorders such as scleroderma have an increased risk for bronchogenic carcinoma in the native lung. In most cases, these are discovered incidentally at the time of transplant during the pathologic examination of the explant [ 63 , 64 ] . The prognosis depends on tumor stage. With the interest in extended donor and recipient criteria such as older age and light smoking history, the incidence of occult carcinomas is likely to expand. Other clinical scenarios for lung cancer in the transplant setting include lung cancer arising in the native lung after transplant and bronchogenic carcinoma occurring in the transplanted lung. An equally unique but controversial group is the cohort of patients transplanted specifi cally for pulmonary adenocarcinoma [ 65 -70 ] . Prior to the recently adopted multidisciplinary classifi cation of lung adenocarcinoma, these tumors were all grouped as "bronchioloalveolar carcinoma " or " BAC ." In the new scheme, tumors formerly called BAC are now classifi ed into nonmucinous lesions [adenocarcinoma in situ ( AIS ) , minimally invasive adenocarcinoma ( MIA ) , lepidic predominant adenocarcinoma ( LPA ) ] and mucinous adenocarcinoma (Fig. 2 ) . The majority of mucinous adenocarcinomas are thought to be invasive based on one or more of the current diagnostic criteria: size (>3 cm), amount of invasion (>0.5 cm), multiple nodules, or lack of a circumscribed border with miliary spread into the adjacent lung tissue [ 71 ] . In a recent review of the topic, Kachala and Murthy identify a total of 70 cases: two of the larger series represent a multicenter collection of data collected by the ISHLT Registry or the United Network for Organ Sharing (UNOS) database, and most of the reported studies are case reports or small case series [ 69 , 70 , 72 ] . None of the reports had rigorous application of the new nomenclature and applied terminology such as "diffuse" or "multifocal BAC ." Nonetheless, there are important points that should be emphasized from the studies. Firstly, although lung transplantation may be considered for highly selected patients with AIS and MIA , there is a signifi cant risk of local recurrence. De Perrot et al. reported recurrences in 13 of the 22 patients who survived the procedure ranging from 5 to 49 month; overall 5-year survival in the group was inferior to the lung transplant group (39 % versus 53 %) [ 69 ] . Bilateral lung transplant may be a superior option to limit recurrences. Secondly, the diagnosis must be established by surgical excision and not a small biopsy to fi rmly establish the pathologic classifi cation ( AIS versus MIA versus PLA). Interestingly, many of the transplant recipients showed a mucinous pattern that would be classifi ed as invasive adenocarcinoma in the current scheme. Thirdly, all patients should be carefully staged to exclude mediastinal nodal involvement. Finally, transplantation should be considered after failure of conventional medical treatment. EGFR mutations can be 

The pathologist plays a critical role in the management of transplant recipients and is a key member of the multidisciplinary team (Table 1 ) . This begins with the confi rmation of the primary lung disease if a biopsy has been previously performed. Generally, this is limited to the surfactant defi ciencies in the infant group and ILD in the adult group. The explanted lung specimen should be carefully evaluated to establish the primary diagnosis and to exclude secondary complications such as infections or occult malignancies [ 74 , 75 ] . In the setting of pulmonary vascular disease, the distinction of IPAH from chronic recurrent thromboembolic disease ( CRPE ) is important as patients with CRPE are at risk for recurrent injury to the allograft. Patients with COPD can harbor occult malignancies such as bronchogenic carcinomas or other smoking-related lesions.

In the perioperative and early postoperative period, PGF must be distinguished from hyperacute rejection ( HAR ) , severe ACR, and infection, as these will have different therapies and potential outcomes. In the later post-transplant setting, the pathologist is responsible for the diagnosis and grading of ACR. As we will discuss in more detail, ACR is a diagnosis of exclusion and a variety of morphological mimics need to be eliminated. Following the institution of augmented immunosuppressive therapy for the treatment of allograft rejection, follow-up biopsies are usually performed to determine treatment effect. Antibody-mediated rejection (AMR) has emerged as a clinicopathologic entity and a multidisciplinary approach for diagnosis and treatment is required.

The diagnosis of chronic airway rejection by transbronchial biopsy ( TBBx ) can be problematic on account of sampling issues. In the setting of diminishing pulmonary function after transplant, careful examination of the small airways is essential to identify obliterative bronchiolitis (OB). Less common fi ndings include posttransplant lymphoproliferative disease ( PTLD ) and recurrence of the primary graft disease. Finally, the important role of the postmortem Table 1 Role of the pathologist in lung transplantation 1. Effective member of multidisciplinary team; openly communicate with clinicians and surgeons 2. Establish pathologic diagnosis on transbronchial or open lung/video-assisted thoracoscopic specimens from native lung prior to transplant 3. Thoroughly evaluate explanted lung(s) to confi rm primary pathological diagnosis and identify additional lung lesions such as infection or occult malignancy 4. Identify etiology of early graft dysfunction such as diffuse primary graft dysfunction/ischemia-reperfusion injury, hyperacute rejection, infection, anastomotic complications in post-transplant biopsy 5. Diagnosis and grade acute cellular rejection using ISHLT criteria and exclude morphological mimics.

Determine effi cacy of anti-rejection or anti-infection therapy in follow-up biopsy specimens 6. Identify histopathologic fi ndings described in antibody-mediated rejection such as neutrophilic margination, neutrophilic capillaritis, or acute lung injury pattern 7. Identify other morphologic causes of graft dysfunction such as aspiration pneumonia, drug toxicity, and infection 8. Identify the presence of obliterative bronchiolitis in late biopsy specimens 9. Diagnose and classify post-transplant lymphoproliferative disorder ( PTLD ) 10 . Establish recurrence of primary parenchymal diseases in the allograft such as sarcoidosis, LAM, hypersensitivity pneumonitis. 11. Preserve tissue or bronchoalveolar lavage specimens for research protocols examination for its clinical and educational functions must be emphasized. We attempt to obtain permission for autopsy evaluation of every deceased thoracic transplant recipient and discuss in detail the clinical and pathological fi ndings in a multidisciplinary setting. It is not uncommon to fi nd clinically signifi cant missed diagnoses in postmortem studies. Akindipe and colleagues found a discrepancy between the autopsy fi ndings and clinically suspected cause of death in 20 % of cases: the most common overlooked diagnoses were HAR , myocardial infarction, pulmonary embolism, high grade ACR, and disseminated fungal infection [ 76 ] .

As discussed previously, there are a variety of indications for transplantation in the pediatric and adult populations. While we generally use a similar approach for handling explanted specimens, it is important to review the electronic clinical records and discuss unusual or uncommon diagnoses with the clinicians prior to the gross dissection. Specimen photography can be a helpful adjunct in the evaluation. The lungs are individually weighed and measured and any missing segments or lobes are noted. The lung explant is usually received in the fresh state and is infl ated through the bronchus with 10 % neutral-buffered formalin or other standard fi xative under slightly elevated passive pressures. We allow overnight fi xation. The pleural surface is examined for adhesions, disruptions, cobblestone change, scars, or retractions. Following retrieval of hilar lymph nodes and an en-face section of the proximal bronchovascular margins, we cut the lung in an axial plane to allow correlation with CT imaging. Sectioning along a sagittal plane is alternative approach for cases of pulmonary hypertension as it enhances the gross alterations of the vasculature. Historically, specimen angiograms or bronchograms were performed primarily as a research protocol [ 77 ] . We recommend at least one section per lobe, all hilar and peribronchial lymph nodes and multiple sections of any gross abnormality found on examination. We routinely perform a silver stain such as a Gomori-methanamine-silver ( GMS ) to exclude fungal airway colonization or active infection. Additional histochemical stains such as elastin and collagen stains for connective tissue or vascular evaluation or stains for microorganisms are obtained on a case-by-case basis.

The gross examination of retransplant and postmortem specimens is similar to the method described in the previous section. In addition to infection and malignancy, the explant is carefully examined for transplant-related changes including ACR, AMR, airway alterations including lymphocytic bronchiolitis (LB) and OB , and parenchymal changes of restrictive allograft syndrome ( RAS ) . We generally submit multiple tissue sections from each transplanted lobe, as lesions can be patchy in distribution. Liberal use of connective tissue stains to evaluate airways for submucosal fi brous thickening and the vessels for transplant vasculopathy is essential. Further, histochemical staining for fungal and mycobacterial organisms and immunohistochemical staining for viral and parasitic inclusions are routinely performed. The histopathologic assessment of AMR is currently done by either immunohistochemistry on formalin-fi xed paraffi n-embedded sections or by immunofl uorescence on freshfrozen tissue samples. The diagnostic criteria will be discussed in detail in another section .

The post-transplant assessment and monitoring of recipients requires a comprehensive multidisciplinary approach. Not surprisingly, these patients are challenging and often have multiple interrelated clinical problems. Frequent clinic visits, serial radiological imaging with radiographs and CT scans, daily spirometric measurements, interval pulmonary function studies, protocol fi beroptic bronchoscopy with bronchoalveolar lavage (BAL) and TBBx , microbiological assessments, nutritional evaluations, measurement of immunosuppressive drug levels, and psychosocial assessments are all part of the complex postoperative management to detect changes in graft function, support patient compliance, augment quality of life, and other critical issues. The use of noninvasive techniques such as gene expression profi ling and circulating cell-free donor-derived DNA ( cfdDNA) to monitor the immunological status of cardiac transplant recipients has been used by some centers, but many of these techniques remain investigative at this time [ 78 -81 ] .

In many centers, surveillance fi beroptic bronchoscopy with BAL and TBBx is a critical component of patient management and the topic was recently reviewed in detail by Glanville [ 82 ] . In some centers, asymptomatic patients are followed without protocol TBBx sampling and they reserve the biopsy for clinical indications such as new onset of symptoms or decline in pulmonary function [ 83 , 84 ] . The goal of surveillance biopsy is the identifi cation of treatable processes such as infection or acute rejection before allograft dysfunction develops, to identify potential risk factors for chronic airway rejection and ultimately to delay or prevent OB. This stems in large part from the poor sensitivity and specifi city of clinical signs and symptoms, radiological techniques and functional techniques in distinguishing acute rejection, infection, and airway anastomotic complications . As a result, the TBBx is widely regarded as the "gold standard" for the evaluation of the pulmonary allograft. TBBx is a safe, invasive procedure in experienced hands, but there are potential serious complications such as bleeding and pneumothorax [ 85 ] . There are also technical and interpretative issues. Many of the pathologic processes affecting the allograft are patchy in distribution and may be "missed" by TBBx ; these include ACR, LB, and OB . The criteria for the diagnosis and reporting of ACR and other forms of allograft rejection were established by the ISHLT and have undergone a series of modifi cations and revisions by the Lung Rejection Study Group in 1996 and 2007 [ 86 -88 ] . Arcosoy et al. [ 89 ] recently reported the interobserver variability for the grading of ACR; a central panel of transplant pathologists reviewed over 1500 biopsies from 845 patients performed at 20 transplant centers. The kappa value for interobserver agreement was 0.183. Cases were upgraded from no rejection to ACR in 9 % of cases, downgraded from treatable rejection categories to no rejection or low-grade rejection in 35 % of cases, and cases of low-grade rejection were downgraded to no rejection in 36 % of cases and upgraded to treatable rejection in 19 % (95 % CI 0.147-0.220). In many cases, the biopsies were deemed "ungradeable" using the ISHLT criteria. In another interobserver study of 59 biopsies for ACR, only moderate agreement was shown between pathologists (kappa 0.470). There was less robust agreement for the diagnosis of either airway infl ammation or OB . Excellent intraobserver agreement, however, was found (kappa 0.795) [ 90 ] . In addition to the interpretative challenges, there are a number of technical issues. Tissue atelectasis and artifactual distortion are found to varying degrees with every TBBx sample. Gentle agitation of the biopsy pieces by a swirling motion of the formalin container can reduce atelectasis. The liberal use of leveled sections and connective tissue stains may resolve the problem of crush artefactual distortion and render a biopsy fragment interpretable in some cases.

The Lung Rejection Study Group of the ISHLT proposed recommendations for tissue handling and processing in the original grading scheme and these have been reiterated in the subsequent revisions. Specifi cally, a minimum of fi ve alveolated pieces that are not completely collapsed should be obtained and immediately fi xed in a standard fi xative such as 10 % neutral buffered formalin. Other fi xatives such as B5 or Bouin's may interfere with immunohistochemistry or other ancillary studies and each lab should carefully establish their optimal thresholds. In the 1990 and 1996 versions, it was recommended that each piece should contain bronchioles and greater than 100 air sacs, but this specifi c requirement was omitted from the 2007 document [ 86 -88 ] . Additional pieces may be necessary if focal processes such as parenchymal nodules or OB are the primary diagnostic considerations. Further, centers that utilize IF staining for the diagnosis of AMR will require one or more additional tissue pieces in saline or another appropriate fi xative before snap freezing. Electron microscopy has no role in routine transplant biopsy evaluation, but may be part of research protocols. It is important to emphasize that frequently fi ve pieces alone will not be suffi cient as one or more piece is composed of entirely of airway wall, strips of airway mucosa, blood vessel, or thrombus and so generous sampling is encouraged.

The transbronchial cryobiopsy ( TCBx ) was recently introduced into clinical practice as part of the multidisciplinary approach to the diagnosis of ILD . Among its advantages are larger pieces of lung tissue without procedure-related hemorrhage or atelectasis. Parajes reported a larger mean area of tissue by cryoprobe (14.7 ± 11 mm 2 ) compared to conventional forceps (3.3 ± 4.1 mm 2 ) ( P < 0.001) [ 91 ] . There are limited published data of TCBx in the lung transplant setting, but early studies suggest a potential role for the procedure with the advantage of larger tissue volume and more airways for evaluation [ 92 , 93 ] (Fig. 3 ) .

The histological assessment of transplant pathology requires optimum handling and processing. Overnight processing in an automated processor is optimal, but a variety of rapid processing programs are available for handling emergent biopsies or clinically indicated biopsies that yield slides in 2-3 h. Following embedding in paraffi n wax, a minimum of three "leveled" sections, each with multiple ribbons, are prepared at 4-5 μm thickness and routinely stained with hematoxylin-eosin (H&E). A connective tissue stain such as Masson's trichrome and/or an elastic stain is helpful for assessing airway and vascular integrity. We still routinely perform a silver stains such as GMS for fungal organisms, but some centers prefer other microbiological, serological, or molecular methods. Additional histochemical stains, immunohistochemistry, and molecular techniques are advocated on a case-by-case basis, e.g., viral infections such as cytomegalovirus ( CMV ) or for the diagnosis and classifi cation of PTLD . Some centers alter the method of slide preparation and obtain seven levels, then stain levels 1, 4, and 7 with H&E, one with elastic trichrome (level 3), 1 with GMS (level 6), and 2 are left unstained for additional stains as necessary [ 94 ] .

In many centers, BAL is used in conjunction with TBBx . It can provide rapid assessment of infection in a patient with clinical deterioration. The specifi c methodologies differ among institutions, but generally small aliquots of normal saline are instilled in the airways and then aspirated by manual or mechanical suction. Fractions of the fl uid are sent for microbiological testing, cytopathologic evaluation, and for cell count and differential quantitation. The exclusion of bacterial or fungal infection is important in the early postoperative period and in patients with chronic airway rejection. Viral organisms can be seen on routine Papanicolaou or May-Grünwald-Giemsastained preparations and fungal organisms can be visualized with fungal stains such as GMS or predigested PAS (Fig. 4 ) . Some centers analyze the functional characteristics of the cells retrieved from the lavage as an adjunct test for infection and acute and chronic rejection [ 95 ] . On occasion, ACR can present with increased levels of eosinophils in the BAL and may predict poorer outcomes [ 96 , 97 ] . BAL characteristics such as the predominance of lymphocytes or neutrophils, the CD4:CD8 ratio, the mean percentage of neutrophils, and lavage levels of myeloperoxidase have been analyzed as predictors of patient outcomes and in patients with BOS [ 98 , 99 ] . 

The role of open lung biopsy ( OLB) and VATS biopsy in the management of transplant recipients has been controversial. Historically, concern for persistent air-leaks or bronchopleural fi stulas limited its indication to seriously ill patients who had failed anti-rejection or antiinfection therapy or who suffered from multiple suspected concurrent processes such as infection and PTLD . A limited number of studies published in the pediatric and adult transplant populations have shown similar fi ndings [ 100 -103 ] . The majority of patients underwent OLB by way of a mini-thoracotomy incision and the biopsies were usually performed in the early or late transplant periods. The most common indications were unexplained deteriorating pulmonary dysfunction after thorough clinical, serological, and bronchoscopic evaluation or the onset of new or persistent pulmonary infi ltrates or nodules. In 30-70 % of cases, a new diagnosis requiring therapeutic intervention or confi rmation of the clinically suspected diagnosis was achieved including acute rejection, OB, organizing pneumonia pattern, infection, and malignancy.

The procedure was found to be most helpful in the early postoperative period to distinguish rejection from infection. There is a role for touch imprints stained with Diff-Quik (Dade-Behring, Newark, NJ) and frozen section examination to provide an initial impression of infection versus rejection versus PTLD and to direct the handling of tissue for special studies such as cytogenetics and molecular analysis. Tissue should always be sent for microbiological cultures. We gently infl ate the wedge biopsy specimen with formalin using a 25-or 27-guage needle (Fig. 5 ) . This promotes tissue expansion of the airspaces and airways and prevents tissue atelectasis and architectural distortion. Following adequate fi xation time of at least 3 h, the wedge is thinly sectioned and submitted for overnight processing. Complications were reported in 5-25 % of cases and ranged from minor issues such as wound infection, postoperative pain, and prolonged airleaks to more serious problems such as respiratory failure and intra-thoracic bleeding requiring surgical re-exploration. Importantly, resolution of air-leaks occurred in all patients, although the course was protracted in some cases. The results of these small numbers of studies and our own experience support the use of VATS biopsy for specifi c clinical indications . 

Akin to the clinical challenges that transplant clinicians face in managing these patients, pathologists recognize that there are a sundry of pathologic processes that can develop in the lung allograft. Fortunately, many of these issues occur within a reasonably narrow temporal framework. PGF and its morphological correlate of diffuse alveolar damage ( DAD ) occur in the early postoperative period. Acute rejection is uncommon during this early period and tends to develop within the fi rst 3-6 months. OB is now uncommon in the fi rst 6 months and typically presents after 1 year. We arbitrarily divide the pathological changes along various time points, but recognize that some disorders such as ACR, AMR, infection, or PTLD can occur anytime following transplantation (Table 2 ).

There is an overlap of clinical and radiologic features for alterations presenting within the fi rst few days or weeks after transplant. These include HAR , PGD , pulmonary venous obstruction, acute left ventricular dysfunction, and overwhelming pulmonary infection with sepsis. The etiology, treatment, and prognosis differ substantially and prompt and accurate diagnosis is essential. Fortunately, other than PGD , most of the disorders in this group are uncommon nowadays.

HAR is a rare, catastrophic complication presenting shortly after revascularization of the allograft. The presence of preformed circulating anti-HLA Type I or II or anti-ABO antibody against donor antigen triggers the complement system resulting in acute clinical dysfunction and morphological alterations. Currently, a handful of case reports have been published detailing the pathological changes [ 104 -111 ] . Clinically, patients present with abrupt onset of respiratory failure with a sharp increase in mean pulmonary artery and airway pressures, release of copious amounts of bloody, frothy fl uid into the airways, dramatic decline in pulmonary compliance, and a drop in both systemic blood pressure and arterial oxygenation. Radiological changes rapidly progress to "whiteout" of the transplanted lung. Of the eight cases detailed in the literature, all but one were female, six occurred in patients with emphysema, fi ve had negative pretransplant studies for panel reactive antibodies (PRA), and three patients had elevated PRA. Death occurred in six patients despite aggressive intervention with plasmapheresis and potent immunosuppressive drugs. Currently, the primary goal is prevention of HAR by identifying patients at high risk, e.g., prior pregnancies, transfusions or transplantation, or underlying connective tissue disorders, and depletion of PRA by plasmapheresis or intravenous immunoglobulin (IVIg) prior to transplant in presensitized patients. The lung in HAR is heavy, fi rm in consistency, and purplish-red in color. Microscopically, the changes range from fl orid pulmonary edema with fi brinous exudates in the airspaces, to conspicuous neutrophilic infi ltrates within the septal walls with necrosis (acute capillaritis) and/or fl ooding of the airspaces with blood and neutrophils to classic DAD with hyaline membrane formation and endothelial and epithelial injury (Fig. 6 ). In the reported cases, platelet-fi brin thrombi in the capillaries and small vessels were inconspicuous or absent. Deposits of immunoglobulin or C4d in the interstitial septal capillaries have been reported .

PGD is currently defi ned by the ISHLT Working Group as acute lung injury (ALI) that occurs within the fi rst 72 h after transplant [ 112 -114 ] . It affects 5-25 % of lung allografts and has previously been termed ischemia-reperfusion injury, reimplantation response and edema, reperfusion edema, early graft dysfunction, post-transplant acute respiratory distress syndrome (ARDS) , and PGF . It exhibits both a clinical and morphological spectrum and the severe form is characterized by acute hypoxemic respiratory failure, diffuse pulmonary infi ltrates on radio-graphs, and DAD in lung biopsy specimens. There is a clinical grading scheme (grades 0-3) for PGD severity based on the partial pressure of oxygen-to-the fraction of inspired oxygen ratio (PaO 2 :FiO 2 ) and the presence or absence of radiological infi ltrates at varying time points (0-6, 24, 48, and 72 h.) after transplant [ 112 ] . PGD , especially Grade 3 PGD , has a signifi cant impact on mortality in the fi rst 30-days and is a risk factor for long-term functional impairment and for the development of chronic allograft rejection in the form of histomorphologic lesion of OB or its clinical correlate of BOS [ 114 -118 ] .

Over the last decade, a number of potential molecular and genetic markers for PGD have emerged and may be helpful in assessing risk stratifi cation before transplant [ 119 -127 ] . Moreover, there are specifi c donor, recipient, and operative variables that promote a clinical predisposition to PGD [ 114 , 115 , 118 ] . Donor risk factors include both inherent and acquired variables such as older or very young donors, African-American race, female gender, history of smoking, prolonged mechanical ventilation, aspiration episodes, head trauma, and hemodynamic instability after brain death. The list of recipient risk factors includes patients with IPAH, elevated pulmonary artery pressures at transplant, obesity, Fig. 6 Hyperacute rejection in patient who developed immediate graft dysfunction following completion of the lung transplant. Edema and scattered interstitial capillary neutrophils indicate early graft injury and patients with diffuse parenchymal lung disease such as sarcoidosis. Prolonged ischemic time, the need for cardiopulmonary bypass, single lung procedures, high FIO 2 requirements at reperfusion, and excessive blood product administration are recognized operative risk variables. The pathogenesis is complicated and multifactorial, but involves free-radical formation, a host of cytokines, and the innate immune response. Treatment is directed at supportive measures, fl uid and electrolyte balances, and prevention of infection and other complications. The clinical differential diagnosis includes HAR , cardiogenic pulmonary edema, venous anastomotic complications/obstruction, and infectious pneumonia, especially viropathic and bacterial types.

There is a morphological spectrum of PGD changes in transbronchial and OLBs. In its mild formulation, neutrophilic infi ltration or sequestration of the alveolar septa, patchy alveolar fi brinous aggregates, and increased pulmonary macrophages are observed. At the severe end of PGD proliferative or organizing phase of DAD with fi broblastic foci, scattered residual hyaline membranes, sparse interstitial infl ammation but widened, edematous septa with fi broblastic aggregates can be present (Fig. 7 ) . The differential diagnosis includes HAR , vascular anastomotic problems with intravascular thrombi, infection, and severe ACR. We routinely perform staining for bacterial and fungal organisms and immunohistochemical staining for viropathic organisms and AMR in this setting and microbiological cultures and serologies (such as viral and donor-specifi c antibody (DSA)) are initiated.

As with anastomotic complications, a variety of donor, recipient, and operative and perioperative factors place the newly transplanted patient at risk for infection and sepsis [ 128 , 129 ] . The intrinsic pulmonary components of lymphatic circulation, ciliary motility, mucous clearance, and neural connections are all disrupted and, together with ischemic injury in the proximal airways, can lead to breakdown of local defense mechanisms. Following transplantation extended ventilatory requirements, line placements, nutritional problems, and diminished ambulation contribute to the development of nosocomial infections. Likewise, recipient factors such as paranasal sinus and airway bacterial colonization in CF patients, smoking history, older age, nutritional and functional deconditioning, and the intense level of immunosuppression after transplant are signifi cant risk factors. The evaluation of potential donors and recipients includes serologic screening for CMV , Epstein-Barr virus ( EBV ) , varicella-zoster , human immunodeficiency virus ( HIV ) , hepatitis B and C . A segment of the distal donor trachea or unused segment of The most common pulmonary infections are bacterial infections and, specifi cally, nosocomial infections. Campos and colleagues [ 130 ] reported Pseudomonas and Staphylococcus as the most common organisms during this period. Nosocomial fungal infections also occur with Candida species making up the majority of cases. Viral, mycobacterial, and parasitic infections are uncommon in this period. Rare donor-derived viral infections that have been reported are HSV in the absence of prophylaxis, lymphocytic choriomeningitis virus, rhabdovirus (rabies), and West Nile virus [ 131 -135 ] .

The incidence of overwhelming infection/sepsis after transplant has greatly diminished over the last two decades. Careful patient (donor and recipient) selection and evaluation, judicious use of antimicrobial prophylaxis, and intensive post-transplant care are largely responsible. Fiberoptic bronchoscopy with BAL and culture are used to establish the diagnosis of most bacterial infections. The typical pattern of acute bronchopneumonia is seen in tissue specimens (Fig. 8 ) . Because of the overlap of features with HAR , careful clinical correlation and histochemical and immunohistochemical staining may be warranted. The diagnosis of rare viral infections require sophisticated molecular testing, while more common viruses like HSV and CMV have characteristic cytopathic features .

Anastomotic complications have been recognized since the early days of lung transplantation [ 7 ] . Historically, rates as high as 60-80 % were recorded, but currently most programs report airway complications in the range of 10-20 % and related mortality rates of 2-3 % [ 136 ] . Vascular and/or airway complications are often multifactorial, infl uenced by donor-related, surgical, and immunosuppressive factors. Colonization of the donor airways by bacteria or fungi, size mismatch of donor and recipient airways or vessels, the use of positive pressure mechanical ventilation and the subsequent tension placed on the anastomosis, devitalization of the proximal airways by bronchial artery ligation, and the delay in graft healing due to immunosuppression all play a role in the initiation and progression of anastomotic problems. King-Biggs and colleagues reported high rates of airway dehiscence in patients receiving Sirolimus in combination with other immunosuppressive drugs when initiated early after transplant [ 137 ] . The overall incidence of airway complications is lower in combined heart-lung recipients than in single or double lung transplant patients.

Although vascular anastomotic complications are less frequent than airway problems, occurring in <2 % of recipients, the clinical implications are more serious. In particular, partial or complete venous obstruction remains a signifi cant cause of early morbidity and mortality if not recognized and urgently treated [ 138 ] . The majority of venous diffi culties occur early after transplant and present with signs and symptoms of persistent pulmonary edema, pleural effusions, hemodynamic instability, high pulmonary capillary pressure, and parenchymal consolidation [ 139 ] . Systemic embolization and stroke are also potential complications of pulmonary vein thrombosis. Complete venous obstruction causes hemorrhagic infarction of the lung if surgical revision of the anastomosis is not performed promptly. Transesophageal echocardiography is an effective modality for assessing the anastomosis and for detecting obstruction. Other techniques that have been used include CT or MRI and CT angiography. Reports of late venous complications have also been reported [ 140 ] . Currently, therapeutic options for vascular disruptions range from medical therapy to either catheter-based interventions with stents or surgical revision [ 141 ] .

Airway complications including infarction, dehiscence, overgrowth by bacteria or fungi, luminal stricture by granulation tissue and scar, bronchomalacia, and fi stula formation are more commonly encountered than vascular problems. The bronchial arteries provide the primary blood supply to the distal trachea and initial 4-5 cm of the bronchi. Ligation of the bronchial arteries places the anastomosis at risk of ischemic injury for the fi rst 2-4 weeks after transplantation. Luminal narrowing by granulation tissue and scar formation can be assessed and classifi ed by a fi beroptic approach, and in some cases, requires laser excision and/or stent placement or even retransplantation (Fig. 9 ) . Some centers advocate bronchial arterial re-anastomosis at the time of transplant to reduce this risk [ 142 ] . Devitalized airways are also sites for colonization of infectious organisms [ 143 ] . We have observed fungal tracheobronchitis and bacterial bronchitis in infarcted airway cartilage .

The common complications encountered in this period are ACR, non-infectious airway infl ammation, AMR, infections, and PTLD . It should be emphasized that there can be both an overlap of morphological fi ndings of these entities and Fig. 9 Ischemic necrosis near the bronchial anastomosis showing devitalized cartilage and necrotic debris synchronous presentation of one or more disorders in a biopsy specimen (e.g., concurrent ACR and AMR).

Most transplant recipients, pediatric and adult alike, will experience at least one episode of ACR. Further, it occurs in all types of transplant including lobar transplants and generally within the fi rst 3-6 months. The Lung Rejection Study Group of ISHLT published the fi rst classifi cation for grading and reporting ACR in 1990 and the scheme was revised in 1996 and again in 2007 [ 86 -88 ] (Table 3 ) . Parenthetically, the current 2007 scheme for ACR is essentially unchanged from the 1990 scheme.

Most patients with ACR are asymptomatic and most biopsies are usually low grade in severity. Even some of our patients with moderate rejection present with limited symptoms. Signs and symptoms are nonspecifi c and include lowgrade fever, cough, hypoxia, drop in expiratory fl ow rates (FEFs), or new onset and/or increase in pulmonary infi ltrates or pleural effusions [ 144 ] . On account of the overlap of clinical and radio-logical fi ndings with infection, imaging techniques are not sensitive or specifi c and PFTs are useful for patient surveillance but not as diagnostic tools [ 145 , 146 ] .

The TBBx has come to be regarded as the "gold standard" for the diagnosis and classifi cation of ACR. As previously discussed, TBBx in most centers is performed as part of a surveillance protocol or for clinical indications with the latter typically demonstrating higher diagnostic yields. The principal histopathologic features of ACR center on the presence of mononuclear infl ammatory cell infi ltrates in the perivascular tissue planes with/without extension along adjacent alveolar interstitial structures and into airspaces. With increasing grades of rejection, the cellular infi ltrates may become more polymorphous with eosinophils and scattered neutrophils and subendothelial mononuclear cell infi ltrates or endothelialitis may be observed. Further, the conducting airways including cartilaginous bronchi and bronchioles can have concurrent lymphocytic mural infi ltrates that are designated as lymphocytic bronchitis or bronchiolitis. The A grade designates the grade of ACR and the B grade designates the airway infl ammation [ 88 ] (Table 3 ) . The immunophenotypic composition of the infi ltrate is CD4+ and CD8+ T-cells, CD68+ macrophages, and CD21+ dendritic cells; CD138+ plasma cells and CD20+ B-cells are uncommon.

A numeric grade cannot be rendered because of insuffi cient (<4-5 adequate) pieces of tissue, crush artefactual distortion, etc.

No perivascular infi ltrates are seen in an adequate biopsy sample.

Limited, infrequent circumferential cuffs of mononuclear infl ammatory cells around one or a few venules or arterioles. Small and large, transformed lymphocytes with occasional plasmacytoid cells form perivascular rings of 2-3 cell layers (Fig. 10 ) . These are generally inconspicuous at low power, but can be detected at high power magnifi cation. 

Perivascular infi ltrates are readily observed at scanning magnifi cations and are composed of more than three cell layers in thickness.

The composition includes small and transformed lymphocytes, macrophages and, not infrequently, eosinophils. The infi ltrates are restricted to the perivascular spaces and do not extend along the alveolar septa (Fig. 11 ) .

Besides the extent of the infi ltrates and the presence of eosinophils in Grade A2, another feature that distinguishes it from Grade A1 is the presence of endothelialitis or intimitis. Further, coexisting airway infl ammation is more common in mild rejection than minimal rejection in our experience. The liberal use of leveled sections rather than immunohistochemistry is often helpful in borderline cases. In most centers, ACR Grade A2 is the threshold for instituting augmented immunosuppression on account of concern for immune-mediated damage of the allograft and the risk of developing CLAD [144] . 

The hallmarks of moderate rejection include the frequency and density of the perivascular cuffs and the extension of the infl ammatory infi ltrates along peribronchiolar alveolar septa and into alveolar spaces (Fig.  12 ) . The latter is often characterized by macrophage and lymphocyte collections within alveolar spaces and type 2 changes of the alveolar epithelium. Endothelialitis is often present and concurrent airway infl ammation may also be found.

We rarely encounter this stage of ACR today. Most patients are symptomatic with marked dyspnea and acute hypoxemia respiratory failure. In addition to the perivascular, interstitial and airspace mononuclear infi ltrates and endothelialitis ACR Grade A4 exhibit parenchymal damage such as alveolar damage, hyaline membranes, necrotic cellular debris, alveolar hemorrhage, and often a conspicuous neutrophilic component (Fig. 13 ) . Vasculitis, The adjacent alveolar tissue showing mixed perivascular infi ltrates and an acute lung injury pattern thrombosis, and parenchymal infarction are seen in the late stages .

There are a number of morphological mimics of ACR. Firstly, perivascular infl ammatory infi ltrates can be found in viral, mycobacterial and fungal infections, and in PTLD . Classically, CMV and Pneumocystis jiroveci pneumonia (PJP) can show perivascular and/or interstitial components (Fig. 17 ) . In CMV pneumonitis , however, there is a predominance of interstitial and septal changes over the perivascular fi ndings. Secondly, prominent perivascular edema, small neutrophilic microabscesses, cytological atypia of the alveolar lining cells, and concurrent acute airway infl ammation favor infection over ACR [ 147 ] . Consequently, the diagnosis of ACR is a diagnosis of exclusion and should be evaluated together with available clinical, serological, immunohistochemical, and microbiologic information. In cases where the distinction remains unresolved, the Lung Rejection Study Group recommends that the pathologist indicates which process is favored and recommend a prompt repeat biopsy after an appropriate period of antimicrobial therapy [ 87 ] . Bronchus-associated lymphoid tissue ( BALT) is part of the normal airway immune defense mechanisms and is composed of mural nodular infi ltrates in small airways (distal small cartilaginous bronchi and terminal bronchioles) at their branching points. In most cases, its nodular confi guration and distribution confi rm the diagnosis. Small vessels in the walls of the airways can display a circumferential infl ammatory cell cuff as part of BALT and should not be confused with ACR. In some cases, the use of additional leveled sections is helpful in demonstrating the airway locale; alternatively, IHC shows collections of CD20+ B-cells in BALT foci. The confusion of BALT for ACR accounted for some of the discrepancy in the ACR readings between local and central pathologists in the study by Arcasoy and colleagues [ 89 ] . Mononuclear cellular collections within interlobular septa in the absence of a perivascular distribution likewise should not be classifi ed as ACR. In some cases, the infl ammatory cells are admixed with anthracotic pigment and macrophage s.

Collections of mononuclear and other infl ammatory cells can be seen in biopsy site changes . On occasion, the TBBx encompasses a focus of a healing or healed site of a prior biopsy. The presence of granulation tissue, hemosiderin-laden macrophages, fi brin, blood, and thrombus are histological clues to this diagnosis.

PTLD is defi ned as a proliferation of lymphoid and/or plasmacytoid cells and is usually EBV -associated. In most cases, these present as solitary or multiple lung masses. An interstitial component with or without perivascular involvement can be seen around the edge of the lesions. A TBBx specimen may yield the periphery of the lesion rather than the central diagnostic component. Communication between the clinical team and the pathologist is essential for proper specimen handling and selection of appropriate immunophenotypic and molecular panels. Interestingly, we have observed both ACR and PTLD in a VATS biopsy and used immunohistochemistry to delineate the different lesions (see also chapter "Transplantation and Malignancy").

A number of technical and interpretative issues related to the ISHLT grading scheme warrant further clarifi cation. Firstly, it is not uncommon to fi nd different patterns of severity of ACR in a transbronchial or VATS biopsy. For example, one piece of tissue may display a pattern of minimal rejection and another show mild or moderate ACR. The designated grade is based on the most advanced grade of rejection and not the predominant pattern. Secondly, some samples may exhibit ACR, but with less than the recommended fi ve pieces of alveolated tissue. We advocate a descriptive diagnosis such as "Mild acute rejection in a suboptimal/borderline adequate sample" and refrain from a numeric grade to alert the clinician to the ACR. The concern for a higher grade of ACR in the lung must be considered in this setting. Thirdly, the diagnosis of ACR requires that the infl ammatory infi ltrate is completely circumferential around the vessel. The arrangement can vary from compact, "tight" collections to more loosely arranged cuffs. The problem of a partial rather than complete cuff is not uncommon. Additional leveled sectioning of the paraffi n block resolves many of these problematic cases. In equivocal cases, we report the fi ndings and recommend careful clinical and microbiological correlation to exclude an infectious etiology. Fourthly, it is not uncommon to fi nd a number of different pathologies in a TBBx sample [ 148 ] . For example, we have observed concurrent cases of ACR and OB in patients transplanted more than 1 year. All signifi cant fi ndings should be documented in the pathology report irrespective of the overall adequacy of the sample.

The clinical signifi cance of Grade A1 or minimal ACR is controversial. Episodes of higher grades of ACR (mild or greater) have been shown to be an independent risk factor for the development of chronic rejection. Recent studies have raised concern that even asymptomatic minimal rejection (Grade A1), including patients with only a single episode, increases the risk for BOS [ 149 -151 ] . As the current threshold for initiating treatment is mild rejection, it is important that the pathologist strictly adhere to the ISHLT diagnostic criteria. In addition, patients with minimal ACR warrant close follow-up and repeat biopsy after a designated interval.

Both the large and small airways are the targets for infl ammation and infection. As described previously, ACR can have concurrent airway mononuclear infl ammatory cell infi ltrates. If other etiologies (especially infection) are excluded, the infi ltrates represent airway rejection. In the absence of ACR, active small airway infl ammation without associated scarring is classifi ed as lymphocytic bronchiolitis , LB . The grading of airway infl ammation has been revised and simplifi ed since the 1990 and 1996 ISHLT versions (Table 3 ) . Currently, the previous minimal and mild LB grades (previously B1 and B2) are compressed to low-grade small airway infl ammation and the numerical grade B1R is used to indicate the revised grade [ 88 ] . Low-grade LB is characterized by submucosal mononuclear infl ammation. The patterns range from patchy or scattered infi ltrates to circumferential bands of mononuclear cells (Fig. 14 ) . Eosinophils are found occasionally, but in small numbers, and by defi nition, mononuclear cells are not seen within epithelial cells. High-grade small airway disease and its numeric counterpart B2R replaced the moderate and severe LB grades (originally B3 and B4) of the previous grading scheme. It is defi ned by the presence of dense mononuclear cells in the bronchiolar submucosa including small and trans- formed lymphocytes admixed with other infl ammatory cells such as eosinophils, neutrophils, and plasma cells in association with intraepithelial infi ltrates and epithelial injury. The degree of epithelial injury ranges from respiratory cell necrosis and metaplasia to epithelial sloughing, ulceration, and cellular and fi brinous exudates (Fig. 15 ) . Grade B0 is defi ned as the absence of airway infl ammation and Grade BX indicates that the biopsy specimen is ungradeable on account of absence of airways, tangential sectioning, artifactual distortion of airways, or infection.

The clinical signifi cance and management of LB is controversial. There is emerging evidence that LB is an independent risk factor for the development of CLAD [ 152 ] . Likewise, it may be a manifestation of AMR, perhaps as a surrogate marker of an activated immune system. Mechanistically, it involves an IL17+ T-cellmediated pathway. The macrolide antibiotic, azithromycin, which has anti-infl ammatory and immunomodulatory properties, has been shown to improve lung function in cases of LB [ 153 , 154 ] .

AMR is now formally recognized as a cause of morbidity and mortality in solid organ transplant recipients. The histopathological and immuno-phenotypic criteria have been recently enumerated in the cardiac allograft [ 155 , 156 ] . Currently, pulmonary AMR is the focus of active multidisciplinary investigation, but the published morphologic experience is limited to case reports and small series [ 157 -176 ] . There is increasing evidence that the 10-30 % of presensitized patients and the 10-50 % of patients who develop donorspecifi c antibodies (DSA) after transplant are at increased risk for ACR, LB, AMR , BOS , and diminished survival [ 177 -181 ] . In addition to DSA , some patients develop non-DSA HLA antibodies and non-HLA antibodies against epithelial, endothelial, or connective tissue antigens such as Type V collagen or K-aplha-1-tubulin [ 182 -184 ] . Some centers utilize prevention and treatment strategies with rituximab and IVIg, or IVIg alone or plasmapheresis alone. Multicenter trials are underway to further evaluate the efficacy of therapeutic intervention for the prevention chronic allograft dysfunction such as BOS in patients who develop anti-HLA antibodies after transplant. These studies emphasize the importance of serological monitoring of patients as part of routine surveillance.

The Pulmonary Working Group of the ISHLT recently convened a group of transplant pulmonologists, surgeons, immunologists, pharmacolo- gists, and pathologists to review the current state of knowledge and to establish working defi nitions and diagnostic criteria for pulmonary AMR [ 185 ] . With the 2005 NIH paradigm of clinical, subclinical, and latent forms of AMR, the group recognized levels of diagnostic certainty with "defi nite, probable and possible" categories of AMR. These categories refl ect the aggregate of clinical, serologic, and pathologic support in a particular case. For example, defi nite clinical AMR is defi ned as the presence of allograft dysfunction, positive DSA, histology suggestive of AMR, and positive C4d staining by IHC or IF. In probable clinical AMR , two of the three features are present and the term possible AMR refl ects the presence of only 1 feature.

The 2007 ISHLT Working Formulation reviewed the published literature and experience of pathologists at that time and proposed recommendations for diagnostic terminology and antibody testing in AMR . The term "acute capillary injury" replaced "acute capillaritis," "septal capillary necrosis," and other descriptions [ 88 ] . In 2012, the Pathology Council of ISHLT refi ned the terminology and proposed specifi c defi nitions for morphologic patterns that have been observed in patients with AMR and recommendations for biopsy and immunophenotypic protocols [ 186 ] . Neutrophilic capillaritis was defi ned as patchy or diffuse alveolar septal neutrophilic infi ltrates containing cellular karyorrhetic debris with or without microvascular thrombi, alveolar hemorrhage, or airspace accumulations of neutrophils. Neutrophilic margination, in distinction, lacked the injurious components. These patterns were identifi ed as infrequent, but reasonably specifi c for AMR. Additional morphologic patterns that were reported in AMR included persistent or recurrent ACR, high-grade LB , OB, ALI with or without hyaline membranes. As previously discussed, ALI can be seen in a variety of lung transplant conditions injury such as infection, high-grade ACR, drug toxicity, and ischemic/ preservation injury. Other pathologic fi ndings that warrant consideration for the possibility of AMR are recurrent/persistent low-grade LB, arteritis in the absence of viral infection, and graft dysfunction that does not reveal a morphologic explanation.

The role of C4d in pulmonary AMR is unsettled at this time. Some centers have shown an association of C4d immunoreactivity with patterns of histopathologic injury enumerated above, while others have suggested that C4d staining is unreliable as a marker of AMR, in distinction to the cardiac and renal transplant experience [ 172 , 175 , 176 ] . When C4d is present, the pattern is weak or strong continuous linear endothelial staining by IHC or IF (Fig. 16 ) . Other structures such as arterial, arteriolar, or venular endothelium, airway basement membrane, vascular elastic membrane, and interstitial septal connective tissue often show C4d staining and serve as internal controls for the purpose of quality control, but are not indicative of AMR . Differential diagnosis of AMR. As noted, the histologic features are nonspecifi c and can be seen in PGD , HAR , non-immunological causes of DAD, severe ACR, and infection. More importantly, these fi ndings should warrant a thorough histochemical, immunohistochemical, molecular, serological (including DSA), and microbiological work-up for other possible causes.

There are a number of unresolved issues besides the utility of C4d staining . As with cardiac AMR, there is likely a morphological spectrum of changes that progress to a diffuse alveolar injury pattern in the allograft. Currently, we perform immunostaining on all TBBx specimens and utilize a limited antibody panel of C4d, CD31, and CMV . We routinely recommend serological DSA studies in this setting and think that the diagnosis of AMR should be made as a diagnosis of exclusion, and only in a multidisciplinary setting of clinical dysfunction, circulating anti-HLA antibodies, and positive pathologic fi ndings. The role of C4d for the diagnosis of AMR is currently under investigation by a number of centers and more studies are needed to determine its utility.

The transplanted lung allograft is at risk for a variety of infectious complications beginning in the immediate post-transplant period and lasting throughout the lifetime of the organ. As previously discussed, a number of immunological, mechanical, and functional factors derived from the donor, recipient, surgical procedure and posttransplant management account for many of these predisposing factors. Not surprisingly, lung transplant recipients are perhaps the most suscep-tible of the solid organ transplant group and this risk extends to all pediatric and adult patients. For example, respiratory viral infections affect more than half of the pediatric recipients [ 187 ] . In our opinion, the most practical approach to the classifi cation of post-transplant infections is the temporal paradigm of Fishman [ 131 ] . In the 1-to 6-month period after transplant when patients are maximally immunosuppressed, opportunistic infections are most commonly encountered. These include the immunomodulating viruses of the herpes group ( CMV , EBV and others), fungal infections caused by Aspergillus species and Pneumocystis jiroveci , bacterial infections such as nocardiosis and mycobacterial infections, and rarely, parasitic infections [ 188 ] . After 6 months, most patients have achieved their lowest maintenance immunosuppression levels and are at risk primarily for community-acquired infections. Importantly, community-acquired respiratory viruses can cause serious clinical infections and trigger acute rejection episodes or promote the development of chronic rejection [ 189 ] . Opportunistic infections can also occur in the late period in patients treated with augmented immunosuppression for recurrent acute rejection episodes or to arrest the progression of BOS . With the widespread use of antimicrobial prophylaxis for specifi c bacterial, viral, and fungal organisms, new patterns and etiologies of infectious complication are now emerging [ 190 ] .

CMV is the most common opportunistic infection in lung recipients as the lung is the principal reservoir for latent CMV virus. The risk is stratifi ed by the CMV status of the donor and recipient. One scenario is primary infection in a seronegative recipient receiving an allograft from a seropositive donor (R-/D+) as this group is at highest risk. Seropositive recipients receiving a lung from either a seronegative donor (R+/D−) or seropositive donor (R+/D+) are at intermediate risk largely by either reactivation or reinfection with a new CMV strain. The group composed of seronegative donor and recipient is at the lowest risk (R-/D-) [ 128 , 191 -193 ] . That said, the terminology used in the literature can be confusing and our approach is based on the following defi nitions:

CMV disease : evidence of CMV infection with attributable symptoms. It can be further classifi ed as CMV syndrome and tissue-invasive disease.

CMV viral syndrome : presence of fever (>38 °C for at least 2 days within a 4-day period), malaise, leukopenia, and thrombocytopenia and the detection of CMV in blood.

Tissue-invasive disease : presence of signs and/ or symptoms of pulmonary disease combined with demonstration of CMV in BAL fl uid or lung tissue specimens by virus isolation, histopathology, and immunohistochemical or in situ hybridization staining.

Prior to the era of CMV prophylaxis , transplant patients typically developed clinical CMV disease (fever, leucopenia, and end-organ involvement) or CMV infection between 1 and 3 months after transplant. CMV prevention is currently focused on prophylaxis strategies like antiviral agents, e.g., oral valganciclovir or oral/ intravenous ganciclovir or CMV preemptive treatment. Prophylaxis programs vary in duration among centers with programs ranging from 1 to 12 months [ 128 , 193 ] . Preemptive strategies are based on careful serologic monitoring with prompt treatment for new onset of CMV infection. Rather than completely eliminating CMV disease, some studies have shown that these programs delay the onset of disease and the problem of "late-onset CMV disease" has emerged in some patients [ 194 ] . In addition to the cost of prophylaxis programs , it should be noted that there are other complications such as drug toxicity, neutropenia, and the development of drug resistance in 10-15 % of patients.

The pathologic diagnosis of tissue-invasive CMV disease requires the identifi cation of the classic amphophilic, large nuclear inclusion separated from the nuclear membrane by a translucent rim or halo with or without cytoplasmic inclusions amidst a variable infl ammatory response (Fig. 17 ) . CMV or "owl's eye" inclusions can be found in pneumocytes, endothelial cells, dendritic cells, macrophages, and smooth muscle cells. The infl ammatory response in a TBBx specimen can range from a sparse interstitial pneumonitis of mixed infl ammatory cells to an ALI pattern with hyaline membranes and microabscesses. Immunohistochemical or in situ hybridization techniques are useful for biopsies demonstrating equivocal fi ndings. Following anti-viral therapy , cells infected by CMV can contain smudgy, inhomogeneous inclusions with irregular outlines and lose the characteristic perinuclear halos.

As discussed earlier, the problem of distinguishing ACR from CMV pneumonitis can be problematic. Perivascular infi ltrates are reported in up to 45 % of biopsies with CMV pneumonitis; endothelialitis, another feature of ACR, can also be found [ 195 ] . In this setting, we recommend anti-viral therapy with an early follow-up biopsy to evaluate for ACR. Subtle clues that favor CMV pneumonitis and other viral infections over ACR include perivascular edema and mixed infl ammatory infi ltrates that contain neutrophils, more loosely arranged perivascular cuffs, and interstitial and septal infi ltrates that predominate over the perivascular component [ 147 ] . Other viruses from the Beta-Herpes group causing graft injury that have been reported in lung recipients are human herpesvirus-6 ( HHV-6 ) and human herpesvirus-7 . PTLD and smooth muscle neoplasms are triggered by EBV [ 193 ] .

Adenovirus and herpes simplex virus pneumonitis are less common opportunistic infections, but can cause severe acute infections. In our experience, adenovirus pneumonia can also progress to or promote chronic rejection. Adenoviral pneumonia is characterized by necrotizing, hemorrhagic bronchopneumonia with irregular ground-glass intranuclear inclusions or smudge cells (Fig. 18 ) . HSV infections create a variety of morphologic patterns such as ulcerative or necro-tizing tracheobronchitis and bronchiolitis, hemorrhagic pneumonia, military nodules, and DAD patterns. Single inclusions or multinucleated giant cell inclusions are typically found within or adjacent to necrotic parenchyma. 

Community-acquired respiratory viral illnesses in lung recipients can be more serious and involve the lower respiratory tract more frequently than in immunocompetent patients. As such, they are associated with higher morbidity and mortality. The most common viruses are respiratory syncytial virus (RSV) , infl uenza A/B, parainfl uenza (serotype 3), metapneumovirus, and rhinovirus. The incidence ranges from 2 to 15 % of recipients [ 196 , 197 ] . The histological fi ndings are usually nonspecifi c and the diagnosis is established by viral culture, fl uorescent antibody, or PCR tests. Another complication of these viruses (except for rhinovirus) is the risk of initiating episodes of acute and chronic rejection .

Fungal infection, despite the reduction in overall incidence due to universal or targeted prophylaxis, remains a signifi cant cause of mortality [ 128 , 129 ] . In the fi rst month after transplantation, infections are either donorderived or related to surgical complications such as airway ischemia. Fungus was identifi ed in 5 % of explanted lungs in one study, again emphasizing the need for comprehensive examination [ 198 ] . The patterns include chronic necrotizing pneumonia, mycetoma, and invasive fungal pneumonia. Fungal infections in the 1-6-month period fungal infections are opportunistic in type with relapsed or residual/persistent infection less frequent causes. Risk factors include recipient native disease, e.g., COPD, ILD , and CF , augmented immunosuppression for acute rejection, and concurrent or recent bacterial or viral infec-tions. After 6 months, fungal infections usually arise after therapeutic interventions for allograft rejection .

The majority of infections are caused by Aspergillus, Candida, Scedosporium, or Cryptococcus species. Of these, Aspergillus infection is the most common. The histopathologic spectrum includes airway dehiscence, vascular anastomotic disruption, tracheobronchitis including ulcerative and pseudomembranous forms, angioinvasive/disseminated parenchymal disease, empyema, aspergilloma, endobronchial stent obstruction, mucoid bronchial impaction, and other patterns of allergic bronchopulmonary aspergillosis [ 199 ] . Fungal tracheobronchitis arises in ischemic segments and is characterized by necrotic cartilage containing hyphal forms (Fig. 19 ) . In angioinvasive fungal pneumonia , parenchymal infarctive necrosis with intravascular plugs of fungi that spill out into the adjacent necrotic parenchyma is observed (Fig. 20 ) . Widely disseminated aspergillosis is less common now, but involvement of the heart, CNS, thyroid, adrenal glands and other sites was typically encountered at postmortem in this setting. Subtle clues for the possibility of airway fungal colonization/infection include the presence of numerous mural eosinophils.

Serious Candida infections are less common today than in the early transplant experience where it accounted for the majority of infections in the fi rst month [ 128 , 129 ] . Identifi cation of Candida mold in BAL fl uid by culture or cytopathology is not uncommon and most represent upper airway colonization. Scedosporium species (formally Pseudoallescheria ) are indistinguishable from Aspergillus on morphology and by radiological techniques. They cause a similar spectrum of disease and have a poorer outcome. They are resistant to amphotericin-B and other polyene antifungal drugs, but respond to azole compounds. Cryptococcus infection is rare in pediatric lung recipients, but in adults is usually the result of reactivation. Unlike the nodular lesions found in immunocompetent hosts, alveolar or interstitial patterns are common in immunosuppressed hosts [ 200 ] .

PJP (formerly Pneumocystis carinii or PCP ) rarely occurs today on account of trimethoprim/ sulfamethoxazole prophylaxis. In our experience, most cases today occur because of poor compliance or drug resistance. The classic radiological appearance is bilateral ground glass opacities. There are a number of histological patterns that range from sparse interstitial lymphoplasmacytic infi ltrates, the classic frothy alveolar exudates, granulomatous lesions, to DAD. Perivascular mononuclear infl ammatory cell infi ltrates that can mimic ACR are reported, so we continue to routinely perform silver stains on TBBx specimens .

PTLD is discussed in detail in the chapter " Transplantation and Malignancy ". Nevertheless, a few features regarding post-transplant lymphop- [ 201 ] .

The association of EBV and smooth muscle neoplasms in immunocompromised patients has been observed in congenital/primary and acquired immunodefi ciency states including HIV and transplant recipients. Over 100 cases have been reported with half arising in solid organ transplant recipients [ 202 -205 ] . Of the 40 cases in the lung, 7 were classifi ed as leiomyosarcoma, 7 as benign leiomyomas, and the remainder as smooth muscle tumors of uncertain malignant potential. They can present as solitary or multiple solid parenchymal masses or as multiple polypoid endobronchial lesions with the morphology of benign leiomyoma. The smooth muscle cells express desmin and caldesmon by IHC and ISH for EBV RNA (EBER) shows strong nuclear staining (Fig. 21 ) .

Drug toxicity is an uncommon but frequently under-recognized problem. Of the many immunosuppressive drugs that lung recipients are required to take daily, the macrolide antibiotic Sirolimus is the one of the more commonly recognized for its pulmonary toxicity. Its immunosuppressive action is directed at inhibition of the mTOR pathway and it has been used clinically since 1999. Initially reported in renal transplant recipients, toxicity occurs in all solid organ recipients [ 206 -211 ] . The histopathologic fi ndings are often nonspecifi c and careful clinical-pathological correlation is required to establish the diagnosis. The histopathologic patterns of injury include an organizing pneumonia pattern, interstitial pneumonitis, pulmonary alveolar proteinosis, patchy fi brosis, alveolar hemorrhage, and granulomatous interstitial pneumonitis (Fig. 22 ) . Withdrawal of the drug and addition of corticosteroid therapy are the mainstay of treatment and most patients improve promptly.

Everolimus is a proliferation signal inhibitor and a derivative of Sirolimus, although it has a shorter half-life and reportedly a wider bioavailability. Unfortunately, it is also associated with pulmonary toxicity with similar nonspecifi c patterns of injury such as cellular interstitial pneumonitis [ 212 , 213 ] . Rituximab is a chimeric anti-CD20 monoclonal antibody used in the treatment of malignant lymphoma and a host of rheumatologic disorders. In lung transplantation, it is used for the treatment of PTLD and AMR and in desensitization protocols. Uncommon but reported pulmonary complications include bronchospasm, interstitial pneumonitis, organizing pneumonia pattern, DAD, ILD with UIP , lymphocytic interstitial pneumonia, or desquamative interstitial pneumonia patterns [ 214 , 215 ] .

The 2007 ISHLT report identifi ed a number of "non-rejection" fi ndings that can be seen in transbronchial or VATS biopsy specimens. These may be of either donor or recipient origin and could warrant further investigation or treatment in some cases. As discussed previously, oropharyngeal dysfunction with aspiration of food and other materials can elicit a foreign body type reaction along with bronchiolitis and organizing pneumonia patterns. Smoking-related lesions such as respiratory bronchiolitis or pulmonary Langerhans' cell histiocytosis could be from a donor with a heavy smoking history, but could be an indication that the recipient is actively smoking. The presence of intravascular talc granulomas or numerous intraalveolar macrophages with anthracotic pigment are indicators of illicit drug use .

In the late period after transplantation , CLAD continues to limit long-term survival in this group. Until recently, CLAD was essentially an obstructive process represented by the histopathologic lesion of OB and BOS as its clinical counterpart. The term has now been broadened to include RAS and a variety of allograft and nonallograft disorders not related to chronic rejection such as neutrophilic-reversible/azithromycin responsive allograft syndrome ( NRAD / ARAD ), GERD, diaphragm dysfunction, and problems in the remaining native lung, etc. [ 216 , 217 ] . Overall, approximately 50 % of transplant recipients develop BOS -or RAS -related CLAD by 5 years following transplant [ 15 ] . The majority of cases of CLAD are associated with BOS (70 %), while nearly 30 % are caused by RAS and the remainder are composed of the non-chronic rejection forms of CLAD [ 218 ] . Other late complications include transplant-associated vasculopathy (TAV), PTLD , and recurrence of the primary lung disease. 

OB / BOS is the most common cause of death or indication for retransplantation in pediatric and adult recipients surviving at least one year. Further, the type of transplant does not provide immunity to this devastating complication. The pathogenesis is complex and a variety of alloimmune and non-alloimmune mechanisms , such as ACR, AMR, LB, increased number of HLA mismatches between donor and recipient, PGD , GERD with aspiration, development of de novo HLA antibodies after transplant, respiratory infections, and microvascular injury of small airways have all been identifi ed as risk factors.

The term bronchiolitis obliterans syndrome was introduced in 1993 and is currently defi ned as an obstructive process characterized by persistent decline in the baseline forced expiratory volume in 1 second (FEV 1 ) or mid-FEF (FEF 25-75 ) over a specifi ed period of time [ 219 , 220 ] . In the latest revision, the concept of partial or complete reversibility is now offi cially recognized [ 221 ] . An essential principle is the exclusion of other causes of airway obstruction such as anastomotic narrowing, infection, acute rejection (ACR or AMR), or recurrent/progressive COPD. The numeric grades of BOS (grade 0-3) refl ect increasing severity of obstruction. Two patterns have been identifi ed on expiratory phase highresolution computed tomography (HRCT) imaging, which predict to some degree of accuracy the responsiveness to azithromycin therapy. The component of bronchiolitis correlates with air trapping or hyperlucency, peribronchiolar thickening, and tree-in-bud alterations, while the OB-related form shows septal thickening, bronchiectasis, and mosaic patterns of parenchymal attenuation [ 222 -225 ] .

The 1990 ISHLT Working Formulation enumerated different patterns of airway luminal alteration along with the presence or absence of an infl ammatory component . The lesions were classifi ed as total or subtotal luminal narrowing and active or inactive depending on the presence or absence of bronchiolar and/or peribronchiolar mononuclear cell infi ltrates [ 86 ] . In the 1996 ISHLT revision, the patterns of "total" and "subtotal" were eliminated, but the designation of infl ammatory activity was retained [ 87 ] . In the 2007 ISHLT Grading Scheme , the classifi cation was further simplifi ed to the absence (grade C0) or presence (grade C1) of OB [ 88 ] (Table 3 ) .

The macroscopic features of OB can be subtle and obscured by adjacent parenchymal infection or scarring. Nodular thickening of bronchovascular bundles can often be palpated. The histopathologic hallmarks of OB are fi broinfl ammatory lesions centered on membranous and respiratory bronchioles and mature, eosinophilic collagenous submucosal fi brosis producing partial or complete obliteration of the lumens (Fig. 23 ). When present, mononuclear infl ammatory cells are distributed within the submucosal In the late cicatricial stages of OB, lumens are fi lled with mature collagenous tissue. Disruption of the elastic membrane and atrophy of the muscular layer of the airway are also seen (Fig. 24 ) . The scar tissue can extend distally into the alveolar ducts and sacs and septal scarring is often present. Mucostasis and/or intraluminal foam cells in the distal airways are useful markers of airway obstruction (Fig. 25 ). Bronchiectasis and bronchiolectasis are usually found at postmortem or at the time of retransplantation in cases of advanced OB, but is not discernible in TBBx specimens [ 226 ] . Bronchiectasis/bronchioloectasis is characterized by mucous plugging, goblet cell hyperplasia, squamous metaplasia, and extensive mural infl ammation.

The clinical course of patients with BOS is variable and diffi cult to predict. Some progress rapidly to end-stage pulmonary failure, while others show periods of stabilization of PFTs. Historically, patients were subjected to trials of high-dose corticosteroid therapy to arrest the pace of functional loss, but current guidelines proscribe against this practice on account of its detrimental side-effects and lack of effectiveness. Therapeutic approaches are now individualized and include substitution of tacrolimus for cyclosporine, a trial of 3 or more months of azithromycin antibiotic, surgical fundoplication for patients with GERD with aspiration, and retransplantation in carefully selected patients [ 217 ] .

Although there is currently no uniformly accepted defi nition of restrictive allograft syndrome (RAS), most patients present with restrictive physiology characterized by a persistent drop in total lung capacity (TLC) >10 % from baseline that is usually accompanied by a drop in FEV 1 of >20 % [ 227 ] . Some centers use forced vital capacity (FVC) and the FEV 1 :FVC ratio as a surrogate marker of TLC [ 228 ] . The prognosis is poor and overall appears to be worse than BOS , although both share similar risk factors [ 229 ] . As this entity has only recently been recognized, the clinical, radiologic, and histopathologic details and diagnostic criteria remain to be fully elucidated. The radiologic fi ndings refl ect the ILD pattern of disease and include traction bronchiectasis, central and peripheral consolidation, pleural thickening, and volume loss in an upper lobepredominant distribution [ 227 , 228 , 230 ] . Interestingly, these fi ndings may be present prior to the onset of changes in pulmonary function tests. The histopathologic fi ndings have been described by Hwang and colleagues from Toronto [ 231 ] from wedge biopsy, postmortem, and retransplant specimens: pleural fi brosis and subpleural fi broelastosis were the most common fi ndings and most patients had concurrent OB either within or adjacent to the fi broelastotic regions and/or regions of DAD (Fig. 26 ) . Paraseptal, centrilobular, and parenchymal fi broelastosis were found in around a third of the cases. There was a sharp delineation of the fi broelastosis from adjacent "normal" lung tissue with foci of organizing pneumonia/fi broblastic foci in the intervening regions. Although honeycomb change was distinctly uncommon, NSIPlike changes were found in up to a quarter of cases. Currently, there is no directed or successful treatment for RAS. There are anecdotal reports of minor responses to pirfenidone and alemtuzumab. Retransplantation has shown poorer 3-year survival in RAS compared to BOS (34 % vs. 68 %) [ 232 ] .

Paraskeva and colleagues from Melbourne [ 233 ] recently reported a series of 22 patients who developed a clinicopathologic form of CLAD that differed from both BOS and RAS . The histopathologic fi ndings were primarily peribronchiolar alveolar airspace accumulations of fi brin without the classic hyaline membranes (Fig. 27 ) . Sparse infl ammation and interstitial thickening were present. The radiologic fi ndings refl ected the morphology with ground glass opacities and interlobular septal thickening; peripheral fi brosis and consolidation were each observed in a quarter of the cases. Patients presented with a fulminant clinical course that rapidly progressed to respiratory failure. There are signifi cant clinical and morphologic differences between acute fi brinoid organizing pneumonia (AFOP), RAS , and BOS (Table 4 ). It is unclear if there is a direct link between AFOP and RAS , but there is limited overlap between the two processes. To date, there are no predisposing risk factors or effective therapies and additional studies are needed. A recent report highlighted a similar histopathologic pattern in infl uenza A/H1N1 pneumonia [ 234 ] .

NRAD or ARAD is another form of CLAD characterized by clinical evidence of BOS , increased numbers of neutrophils in BAL samples, and improvement of PFTs (increased FEV 1 ) following a prolonged (2-3 month) course of neomacrolide antibiotics like azithromycin [ 216 , 235 ] . Several studies have shown that BAL neutrophilia at 3 and 12 months following transplant is predictive for the development of BOS . The mechanism is likely through repetitive epithelial injury and fi broinfl ammatory airway injury by neutrophilic release of matrix metalloproteinases, chemokines, growth factors, and oxidative stress. Azithromycin exhibits both antimicrobial and anti-infl ammatory effects, and in some studies, up to 40 % of patients with BOS showed sustained improvement in their FEV 1 of >10 % and a small number of patients reversed their BOS score to BOS 0 [ 236 , 237 ] . Some investigators have recommended a trial of azithromycin therapy for all patients with BOS (regardless of BAL neutrophils counts) . 

The arteries and veins in the lung allograft are susceptible to the development of TAV. The lesions share the same fi brointimal alterations that are observed in other solid organ transplants and are currently designated as Grade D in the 2007 ISHLT Working Formulation. Coronary artery TAV is a frequent complication in combined heart-lung recipients [ 238 ] . In our experi-ence, these lesions are easily found in retransplant and postmortem specimens, but are uncommon in TBBx specimens. A connective tissue stain is often helpful in outlining the components of vessels. TAV lesions usually accompany OB and are generally clinically insignifi cant (Fig. 28 ) . A recent study reported hemodynamic evidence of pulmonary hypertension in some patients [ 239 ] . Concentric intimal thickening composed of smooth muscle cells and myofi broblasts, variable lymphocytes, and macrophages including foam cells are found. On occasion, superimposed thrombosis complicates the lesions. Intimal sclerosis of veins and venules is commonly found in TBBx specimens and should not been designated as chronic rejection in isolation .

As previously discussed, recurrence of lung adenocarcinoma has been documented in the allograft and is one argument against transplantation for this diagnosis. Other disorders have been reported in the transplanted lung including an array of smoking-related and different ILD patterns such as pulmonary Langerhans' cell histiocytosis, desquamative interstitial pneumonia (DIP), bronchiolitis-respiratory-interstitial lung disease (RBILD), and hypersensitivity pneumonitis. With the exception of PVOD and PCH recurrent pulmonary vascular disorders such as IPAH have not been recorded (Table 5 ). In our experience, sarcoidosis and lymphangioleiomyomatosis are the most common lesions and are usually detected as incidental fi ndings on surveillance TBBx [ 61 , 240 -248 ] . The histopathological changes are similar to the native disease (Fig. 29 ) . Awareness of the pretransplant diagnosis is essential prior to evaluating any TBBx . Infection should always be excluded in cases of granulomatous pneumonitis following transplantation.

Over the last 35 years, there has been tremendous progress in the fi eld of lung transplantation. That said, there are a number of issues that need to be resolved if the survival rates at 1-, 5-, and 10-years are to reach the same level as other solid organ transplant programs. There continues to be refi nement of selection criteria and expansion of both the indications for transplant and the overall number of candidates. The need for increasing the donor pool is critical. The use of "marginal" and reconditioned organs through EVLP has helped to identify organs that previously would have been considered unsuitable for transplant. Currently, there are only a few clinical EVLP programs in Europe and North America. With their continued achievements, the technology should become routine in most centers in the near future. This needs to be balanced with the risks of infection and PGD and their effects on overall survival, morbidity, and the risks for the development of CLAD. The therapeutic armamentarium must be expanded beyond conservative postoperative management for PGD and new interventions besides inhaled nitric oxide, inhaled surfactant, and C1-estaerase-inhibition must be found.

The diagnosis and treatment of ACR has become standardized and severe ACR is now uncommon. There have been very few new immunosuppressive drugs over the last decade in part because the challenges of drug development and multicenter trails are now daunting. Akin to the developments in PGD , the ideal approach would be to create personalized patient profi les through molecular technologies that would optimize immunosuppressive drug regimes, identify risks for infection, and CLAD. As the diminished costs and ever-increasing sophistication of molecular testing evolve, the concept of "precision transplant medicine" may become routine. AMR has become a recognized but perplexing entity in lung transplantation. The role of de novo DSA in the development of acute graft failure and later complications such as BOS and RAS is fi rmly established from the medical literature. With the recent formulations of defi nitions and Table 5 Recurrent pulmonary disorders in the lung allograft Sarcoidosis Lymphangioleiomyomatosis Pulmonary adenocarcinoma Desquamative interstitial pneumonia (DIP) Giant cell interstitial pneumonia (GIP) Hypersensitivity pneumonitis Pulmonary alveolar proteinosis (PAP) Idiopathic pulmonary hemosiderosis (IPH) Diffuse panbronchiolitis Pulmonary Langerhans' cell granulomatosis Pulmonary veno-occlusive disease diagnostic criteria, clinicians now have the opportunity to investigate AMR at multiple levels. The role of histopathology and immunopathology in particular is unsettled at this time. To date, there are no diagnostic histopathologic features for AMR and those with acceptable speci-fi city appear to be infrequent. Likewise, C4d immunostaining appears to be an infrequent fi nding in patients with allograft dysfunction and de novo DSA. A more specifi c set of pathologic markers will likely be required. At the present time, however, the pathologist plays an important CLAD has now evolved from the singular BOS to a number of additional entities such as RAS and neutrophilic-reversible/azithromycinsponsive allograft dysfunction. Unfortunately, CLAD continues to limit long-term survival and the pathogenesis is both complex and multifactorial. Like AMR, it requires a multidisciplinary approach for diagnosis and treatment options remain limited. The identifi cation of azithromycin as a novel therapeutic intervention for airway infl ammation in patients with BOS provides at least a temporizing step. Unfortunately, until more precise pathogenetic mechanisms are elucidated, preventative methods remain elusive.

The role of artifi cial lung technology and xenotransplantation in clinical lung transplant provides exciting theoretic options for addressing the shortage of donors. Improvements in ECMO technology and mounting clinical experience provide clinicians with opportunities to bridge patients to either recovery or transplant. Progress continues in bioartifi cial lung technology and tissue engineering through decellularization and reconstitution with stem cells such as induced pluripotent stem cells. There are a variety of technical and immunologic hurdles, but the concept of tissue engineered lung transplantation is an exciting endeavor [ 249 ] . Work on xenotransplantation continues in a limited number of centers. Like tissue engineering, there are daunting technical, immunologic, and ethical barriers that will need to be resolved in the future.

The future brings many challenges and the pathologist will continue to be an integral member of the multidisciplinary transplant team.

Overview of lung transplantation

Transplantation of the heart and both lungs: I Historical review

A testimony to the history of heart and lung transplantation: English translation of Demikhov's paper

Lung homotransplantations in man: report of the initial case

Human lung homotransplantations

Organ transplantation for advanced cardiopulmonary disease

A review of 23 human lung transplantations by 20 surgeons

Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease

Unilateral lung transplantation for pulmonary fi brosis

Technique of successful clinical double-lung transplantation

Lobar transplantation. Indications, technique, and outcome

RELIVE Study Group. Morbidity and mortality of live lung donation: results from the RELIVE study

Living-donor lobar lung transplantation provides similar survival to cadaveric lung transplantation even for very ill patients

Lobar lung transplantation: a relevant surgical option in the current era of lung allocation score

The Registry of the International Society for Heart and Lung Transplantation: Thirty-second offi cial adult lung and heart-lung transplantation report-2015; focus theme: early graft failure

The Registry of the International Society for Heart and Lung Transplantation: Eighteenth offi cial pediatric lung and heart-lung transplantation report-2015; focus theme: early graft failure

Development of the new lung allocation system in the United

The impact of the lung allocation score

Increasing lung allocation score predict worsened survival among lung transplant recipients

Impact of the lung allocation score on survival beyond 1 year

Double lung transplants have significantly improved survival compared with single lung transplants in high lung allocation score patients

Pediatric lung allocation: the rest of the story

The equitable allocation of deceased donor lungs for transplant in children in the United States

Lung and heart allocation in the United States

ABOincompatible lung transplantation in an infant

International Society for Heart and Lung Transplantation A review of lung transplant donor acceptability criteria

Donor selection and management

A strategy to increase the donor pool: use of cadaver lungs for transplantation

Non-heart-beating donors in thoracic transplantation

Cadaver lung donors: effect of preharvest ventilation on graft function

Non-heart-beating lung donation in the Netherlands: the fi rst experience

Early lung transplantation success utilizing controlled donation after cardiac death donors

Early experience with lung transplantation using donors after cardiac death

Lung transplantation from donation after cardiocirculatory death: a systematic review and meta-analysis

Long-term results after lung transplantation using organs from circulatory death donors: a propensity score-matched analysis

Transplantation of lungs from a nonheart-beating donor

Technique for prolonged normothermic ex vivo lung perfusion

Functional repair of human donor lungs by IL-10 gene therapy

Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo

Normothermic ex vivo lung perfusion in clinical lung transplantation

Lung transplantation with donation after circulatory determination of death donors and the impact of ex vivo lung perfusion

Pre-implantation multiple cytokine mRNA expression analysis of donor lung grafts predicts survival after lung transplantation in humans

Impact of human donor lung gene expression profi les on survival after lung transplantation: a case-control study

Pilot study exploring lung allograft surfactant protein A (SP-A) expression in association with lung transplant outcome

Impact of cytokine expression in the pre-implanted donor lung on the development of chronic lung allograft dysfunction subtypes

Expression profi ling of human donor lungs to understand primary graft dysfunction after lung transplantation

Gene set enrichment analysis identifi es key innate immune pathways in primary graft dysfunction after lung transplantation

International Guidelines for the Selection of Lung Transplant Candidates

Pulmonary Scientifi c Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientifi c Council of the International Society for Heart and Lung Transplantation

A consensus document for the selection of lung transplant candidates: 2014-an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation

Guidelines for the selection of lung-transplant candidates

Growing experience with extracorporeal membrane oxygenation as a bridge to lung transplantation

Effi cacy of extracorporeal membrane oxygenation as a bridge to lung transplantation

Extracorporeal membrane oxygenation as a bridge to pulmonary transplantation

ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fi brosis

Lung transplant outcomes in cystic fi brosis patients with pre-operative Mycobacterium abscessus respiratory infections

Lung transplantation for patients with cystic fi brosis and Burkholderia cepacia complex infection: a single-center experience

Pathologic fi ndings in lung volume reduction surgery

Updated clinical classifi cation of pulmonary hypertension

Advances in the understanding and classifi cation of pulmonary hypertension

Recurrent pulmonary capillary hemangiomatosis after bilateral lung transplantation

Simultaneous thoracic and abdominal transplantation: can we justify two organs for one recipient?

Primary lung cancer in lung transplant recipients

Prevalence and outcome of lung cancer in lung transplant recipients

Successful double-lung transplantation for bronchioalveolar carcinoma

Recurrence of bronchioloalveolar carcinoma in transplanted lungs

Lung transplantation for advanced bronchioloalveolar carcinoma confi ned to the lungs

Pulmonary transplantation for advanced bronchioloalveolar carcinoma

Role of lung transplantation in the treatment of bronchogenic carcinomas for patients with end-stage pulmonary disease

Outcomes for lung transplantation for lung cancer in the United Network for Organ Sharing Registry

International Multidisciplinary Classifi cation of Lung Adenocarcinoma

Lung transplantation for multifocal lung adenocarcinoma (multifocal lung carcinoma)

Refi ning the treatment of NSCLC according to histological and molecular subtypes

Audit of referral and explant diagnoses in lung transplantation: a pathologic study of lungs removed for parenchymal disease

Singlelung transplant complicated by unexpected explant carcinoma: a management dilemma

Discrepancies between clinical and autopsy diagnoses in lung transplant recipients

Pathologic pulmonary alterations in long-term human heartlung transplantation

Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection

Experience with monitoring in lung transplant recipients: correlation of low immune function with infection

Gene-expression profi ling for rejection surveillance after cardiac transplantation

Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection

The role of surveillance bronchoscopy post-lung transplantation

Success of lung transplantation without surveillance bronchoscopy

Single-institution study evaluating the utility of surveillance bronchoscopy after lung transplantation

Safety and effi cacy of outpatient bronchoscopy in lung transplant recipients -a single centre analysis of 3,197 procedures

A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung Rejection Study Group. The International Society for Heart Transplantation

Revision of the 1990 working formulation for the classifi cation of pulmonary allograft rejection: Lung Rejection Study Group

Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection

Pathologic interpretation of transbronchial biopsy for acute rejection of lung allograft is highly variable

Interpretation of transbronchial biopsies from lung transplant recipients: interand intraobserver agreement

Diagnostic yield of transbronchial cryobiopsy in interstitial lung disease: a randomized trial

Transbronchial cryobiopsy in immunocompromised patients with pulmonary infi ltrates: a pilot study

Comparison of transbronchial cryobiopsies with conventional forceps biopsies in evaluation of lung allografts

Approach to a lung transplant biopsy

Elevated CXCL10 (IP-10) in bronchoalveolar lavage fl uid is associated with acute cellular rejection after human lung transplantation

Eosinophilic alveolitis in BAL after lung transplantation

Elevated bronchoalveolar lavage eosinophilia correlates with poor outcome after lung transplantation

Persistent increases of BAL neutrophils as a predictor of mortality following lung transplant

Bronchiolitis obliterans syndrome in lung transplant recipients is associated with increased neutrophil activity and decreased antioxidant status in the lung

Role of open lung biopsy for diagnosis in lung transplant recipients: ten-year experience

The utility of open lung biopsy following lung transplantation

Role of open lung biopsy in transplant recipients in a single children's hospital: a 13-year experience

Invasive biopsy is effective and useful after lung transplant

Hyperacute rejection following lung transplantation

Hyperacute rejection of a pulmonary allograft: immediate clinical and pathologic fi ndings

Susceptibility of lung transplants to preformed donor-specifi c HLA antibodies as detected by fl ow cytometry

Hyperacute rejection in single lung transplantation-case report of successful management by means of plasmapheresis and antithymocyte globulin treatment

Hyperacute rejection after lung transplantation caused by undetected lowtiter anti-HLA antibodies

Hyperacute rejection after single lung transplantation: case report

Treatment of hyperacute antibody-mediated lung allograft rejection with eculizumab

Fulminant hyperacute rejection after unilateral lung transplantation

Report of the ISHLT working group on primary graft dysfunction Part II; Defi nition. A consensus statement of the International Society for Heart and Lung Transplant

Primary graft dysfunction

Lung Transplant Outcomes Group. Clinical risk factors for primary graft dysfunction after lung transplantation

Report of the ISHLT working group on primary graft dysfunction. Part V predictors and outcomes

Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome

Late primary graft dysfunction after lung transplantation and bronchiolitis obliterans syndrome

Short-and long-term outcomes of 1000 adult lung transplant recipients at a single center

A panel of lung injury biomarkers enhances the defi nition of primary graft dysfunction (PGD) after lung transplantation

Latent class analysis identifi es distinct phenotypes of primary graft dysfunction after lung transplantation

Plasma complement levels are associated with primary graft dysfunction and mortality after lung transplantation

Lung Transplant Outcomes Group. Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction

C1-esterase-inhibitor for primary graft dysfunction in lung transplantation

Interleukin-17 receptor polymorphism predisposes to primary graft dysfunction after lung transplantation

Lung Transplant Outcomes Group Investigators. Oxidant stress regulatory genetic variation in recipients and donors contributes to risk of primary graft dysfunction after lung transplantation

Lung Transplant Outcomes Group. Preoperative plasma club (clara) cell secretory protein levels are associated with primary graft dysfunction after lung transplantation

Objective estimates improve risk stratifi cation for primary graft dysfunction after lung transplantation

Pulmonary infections following lung transplantation

Lung transplant infection

Bacterial and fungal pneumonias after lung transplantation

From the classic concepts to modern practice

Transmission of lymphocytic choriomeningitis virus by organ transplantation

Management and outcomes after multiple corneal and solid organ transplantations from a donor infected with rabies virus

An update on donor-derived disease transmission in organ transplantation

LCMV Transplant Investigation Team. Solid organ transplant-associated lymphocytic choriomeningitis

Airway complications after lung transplantation

Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation

Vascular anastomotic complications in lung transplantation: a single institution's experience

Pulmonary venous obstruction after lung transplantation. Diagnostic advantages of transesophageal echocardiography

Late pulmonary venous complications after transplantation

Endovascular management of early lung transplant-related anastomotic pulmonary artery stenosis

Comparative study of bronchial artery revascularization in lung transplantation

Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis

Acute cellular and antibody-mediated allograft rejection

Acute lung rejection after heartlung transplantation: correlation of fi ndings on chest radiographs with lung biopsy results

High-resolution computed tomographic fi ndings associated with histologically diagnosed acute lung rejection in heart-lung transplant recipients

Pulmonary infections in transplantation pathology

The puzzling coexistence of different histological changes in the same transplanted lung

Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis

Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome

The signifi cance of a single episode of minimal acute rejection after lung transplantation

Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation

Anti-infl ammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection

Azithromycin and the treatment of lymphocytic airway infl ammation after lung transplantation

The ISHLT working formulation for pathologic diagnosis of antibodymediated rejection in heart transplantation: evolution and current status

International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation

Humoral (antibody-mediated) rejection in lung transplantation

Pulmonary capillaritis: a possible histologic form of acute pulmonary allograft rejection

Humorally mediated posttransplantation septal capillary injury syndrome as a common form of pulmonary allograft rejection: a hypothesis

Evidence that humoral allograft rejection in lung transplant patients is not histocompatibility antigen-related

Acute humoral rejection of human lung allografts and elevation of C4d in bronchoalveolar lavage fl uid

HLA-specifi c antibodies are associated with high-grade and persistentrecurrent lung allograft acute rejection

Pulmonary capillaritis in lung transplant recipients: treatment and effect on allograft function

C4d deposition in lung allografts is associated with circulating anti-HLA alloantibody

C4d staining of pulmonary allograft biopsies: an immunoperoxidase study

C3d and the septal microvasculature as a predictor of chronic lung allograft dysfunction

Anti-human leukocyte antigen antibodies, vascular C4d deposition and increased soluble C4d in broncho-alveolar lavage of lung allografts

Pulmonary capillaritis as a manifestation of acute humoral allograft rejection following infant lung transplantation

Acute antibody-mediated rejection after lung transplantation

Acute humoral rejection in a lung recipient: reversion with bortezomib

Positive virtual crossmatch with negative fl ow crossmatch results in two cases

The histopathology of lung allograft dysfunction associated with the development of donor-specifi c HLA antibodies

Diagnosis and treatment of antibody mediated rejection in lung transplantation: a retrospective case series

Acute antibody-mediated rejection after lung transplantation

Pathologic fi ndings in lung allografts with anti-HLA antibodies

Banff Study of Pathologic Changes in Lung Allograft Biopsies with Donor Specifi c Antibodies

Donorspecifi c antibodies are associated with antibodymediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fi brosis after lung transplantation

Pre-transplant donor HLA-specifi c antibodies: Characteristics causing detrimental effects on survival after lung transplantation

De novo donor HLA-specifi c antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation

The impact of pretransplant allosensitization on outcomes after lung transplantation

Antibody mediated rejection

Antibodies to K-alpha 1 tubulin and collagen V are associated with chronic rejection after lung transplantation

Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance

Role of anti-vimentin antibodies in allograft rejection

Antibody mediated rejection of the lung: an ISHLT consensus report

Pathology of pulmonary antibody-mediated rejection:2012 update from the Pathology Council of the ISHLT

Long-term impact of respiratory viral infection after pediatric lung transplantation

Early and late infections in lung transplantation patients

Rhinovirus and other respiratory viruses exert different effects

Emerging bacterial, fungal, and viral respiratory infections in transplantation

ATS Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients

Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation

DNA viral infections complicating lung transplantation

Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis

The role of transbronchial biopsies in the management of lung transplant recipients

Community-acquired respiratory infections in lung transplant recipients

Community-acquired respiratory viruses after lung transplantation: common, sometimes silent, potentially lethal

Impact of mold infections in explanted lungs on outcomes of lung transplantation

The clinical spectrum of pulmonary aspergillosis

Pulmonary cryptococcosis: CT and pathologic fi ndings

Discrimination of Epstein-Barr virus-related posttransplant lymphoproliferations from acute rejection in lung allograft recipients

Epstein-Barr Virus-associated smooth muscle tumors are distinctive mesenchymal tumors refl ecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients

Molecular and clinicopathological analysis of Epstein-Barr virus-associated posttransplant smooth muscle tumors

Epstein-Barr virus-associated pulmonary smooth muscle tumor after lung transplantation

Epstein-Barr virus-associated smooth muscle tumors in children following solid organ transplantation: a review

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients

Sirolimusassociated pulmonary toxicity

Patterns of pulmonary complications associated with sirolimus

Interstitial pneumonitis in the transplant patient: consider sirolimus-associated pulmonary toxicity

Sirolimus induced granulomatous interstitial pneumonitis

Sirolimus-induced bronchiolitis obliterans organizing pneumonia in kidney transplant recipient; a case report and review of the literature

Everolimus-related pulmonary toxicity in heart transplant recipients

Everolimus-associated pneumonitis in 3 heart transplant recipients

Rituximab-induced interstitial lung disease: case report and literature review

Non-infectious pulmonary toxicity of rituximab: a systematic review

A new classifi cation system for chronic lung allograft dysfunction

Chronic lung allograft dysfunction

Restrictive chronic lung allograft dysfunction: where are we now?

A working formulation for the standardization of nomenclature for clinical staging of chronic dysfunction in lung allografts: International Society for Heart and Lung Transplantation

Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria

ISHLT/ATS/ERS BOS Task Force Committee. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome

Bronchiolitis obliterans after lung transplantation: detection using expiratory HRCT

Bronchiolitis obliterans syndrome in heart-lung transplant recipients: diagnosis with expiratory CT

Bronchiolitis obliterans following lung transplantation: early detection using computed tomographic scanning

Thin-section computed tomography fi ndings before and after azithromycin treatment of neutrophilic reversible lung allograft dysfunction

The pathology of combined heart-lung transplantation: an autopsy study

Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction

Survival determinants in lung transplant patients with chronic allograft dysfunction

Bronchiolitis obliterans syndrome and restrictive allograft syndrome: do risk factors differ?

Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction

Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fi broelastosis

Survival after redo-lung transplantation for CLAD according to phenotype: a multi-center study

Acute fi brinoid organizing pneumonia after lung transplantation

Acute fi brinous and organizing pneumonia associated with infl uenza A/ H1N1 pneumonia after lung transplantation

Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation

Azithromycin reverses airfl ow obstruction in established bronchiolitis obliterans syndrome

Neutrophilic reversible allograft dysfunction (NRAD) and restrictive allograft syndrome (RAS)

Accelerated posttransplant coronary arteriosclerosis in combined heart-lung transplantation

Pulmonary hypertension associated with lung transplantation obliterative bronchiolitis and vascular remodeling of the allograft

Recurrent sarcoidosis in lung transplant allografts: granulomas are of recipient origin

Lymphangioleiomyomatosis: recurrence after lung transplantation

Recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation

Recurrence of desquamative interstitial pneumonia after lung transplantation

Giant cell interstitial pneumonitis. Disease recurrence in the transplanted lung

Recurrence of idiopathic pulmonary hemosiderosis in a young adult patient after bilateral single-lung transplantation

Lung transplantation for pulmonary Langerhans' cell histiocytosis: a multicenter analysis

Recurrence of pulmonary veno-occlusive disease after heart-lung transplantation

Lung transplantation for hypersensitivity pneumonitis

Future prospects for tissue engineered lung transplantation: decellularization and recellularization-based whole lung regeneration